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ABSTRACT 
 
A key enabling technology in biological sciences involves fluorescent probes. These 
probes are typically small molecules, proteins, or nucleic acids that either possess 
intrinsic fluorescence or are linked to a fluorophore that emits photons and can be 
detected by techniques such as fluorescence spectroscopy, imaging, or flow cytometry. 
In early-stage drug discovery projects, fluorescent probes can be used to sort and 
differentiate particular types of cells, conduct high-throughput screening campaigns, and 
image subcellular compartments. In this dissertation, I describe the use of fluorescent 
probes to study microtubules and mitochondria in living cells. These structures and 
organelles are of substantial interest in fundamental cellular biology and as targets of 
anticancer agents. One of these projects is focused on the anticancer agent Paclitaxel 
(Taxol). This small molecule that binds microtubules and is one of the most effective 
treatment for patients with breast, ovarian, and lung cancers. Remarkably, although Taxol 
can shrink slow-growing tumors in some patients, this drug spares rapidly proliferating 
cells such as bone marrow cells. This inconsistency has been termed the proliferation 
rate paradox and is not well understood. To probe the mechanism of action of Taxol, we 
designed and synthesized a drug-like fluorescent probe termed PB-Gly-Taxol. This 
compound recapitulates many aspects of the biological properties of Taxol in cells, and 
provides a new tool to study proliferation rate paradox. In a second project, I describe the 
discovery of a small molecule termed 2,7-difluoropyronin B that accumulates in 
hyperpolarized mitochondria of cancer cells. When irradiated with visible blue light, this 
probe depolarizes mitochondrial membranes, offering a new chemical tool for 
photochemical control over mitochondrial biology.  
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Chapter 1 - Introduction 
 
 
1.1 Fluorescent probes for studies of cancer and other biological systems 
Cancer is a major cause of human death. According to the World Health 
Organization (WHO), an estimated 9.6 million people died from cancer in 2018, with one 
in six deaths due to cancer. In 2015, patients in the USA paid approximately $80.2 billion 
for medical treatment, according to the Agency for Healthcare Research and Quality 
(AHRQ). This huge financial burden is projected to reach at least $158 billion in the US 
by 2020, according to the National Institutes of Health (NIH). As a consequence, every 
year billions of dollars are invested on medical research both in academia and industry, 
and the annual total budget of the National Cancer Institute (NCI) is ~ $5 billion. However, 
despite this large investment, scientific advances for the treatment of cancer are 
challenging because this condition is an extensive collection of diseases that are 
characterized by abnormal cell proliferation. More than 100 types of cancer have been 
identified, including breast cancer, prostate cancer, lung cancer and colon cancer, to 
name the most common types. Due to the innate complexity of this disease, it is difficult 
but crucial to study the different mechanisms of cancer initiation and progression and 
discover drugs and improved treatments.  
A great deal of research on cancer biology involves the use of chemical probes. In 
general, a probe is a molecule that specifically interacts with an analyte of interest in a 
biological system such as cells in culture or an animal model. The analyte is usually a 
biomolecule such as a protein or nuclei acid. A fluorescent probe is a chemical probe with 
intrinsic fluorescence or is tagged with a fluorophore that emits fluorescent photons that 
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can be detected by techniques such as confocal microscopy or flow cytometry. Some 
fluorescent proteins are also used in this way, but compared to fluorescent proteins, 
fluorescent small molecule probes can in many cases be readily synthesized, are more 
chemically and optically stable, and may be less likely to perturb biological systems under 
investigation. 
 
1.2 The use of fluorescent probes for cell sorting 
 Isolating and sorting a specific cell population from a heterogonous mixture is very 
important method in biological research, clinical diagnosis, and drug discovery. This 
approach offers a tool for scientists to pinpoint the mechanism of diseases and find potent 
therapeutic treatment for patients. For example, the first FDA-approved CellSearch blood 
test aids in the treatment of metastatic cancer patients by capturing, isolating and 
enumerating circulating tumor cells (CTC), a rare cell derived from a solid tumor that is 
capable of spreading throughout the body.1  
 
1.2.1 Fluorescence-activated cell sorting 
Many cell sorting technologies have been developed including magnetic-activated 
cell sorting (MACS) and fluorescence-activated cell sorting (FACS). Although MACS 
devices are significantly cheaper than FACS, MACS often retains non-labeled cells with 
the desired target cells, and it may poorly capture target cells far from the field source 
due to non-linear magnetic forces, limiting its application.2 The first commercial FACS 
instrument was invented in 1969 by Dr. Herzenberg and his colleagues.3 FACS is now 
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considered the gold standard for separating cells through the use of fluorescent dyes, 
fluorescent labeled antibodies, or genetically modified proteins bearing a fluorescent tag.  
Early applications of FACS relied on small-molecule fluorescent dyes to sort cells 
based on the observation of unique biological properties. For example, one of the most 
widely used cell separation methods uses the small molecule propidium iodide (PI, 1 in 
Figure 1.1) to differentiate dead cells from living ones.4 This assay is based on the ability 
of PI to enter cells with disrupted membranes, but this dye is excluded from cells with 
intact membranes. Once PI enters a cell, it intercalates into DNA in the nucleus and upon 
excitation, it emits red fluorescent photons. The resulting differences in cellular 
fluorescence can be used to separate dead from living cells. This method has been 
applied to numerous studies of cytotoxicity and membrane leakage in cancer biology. 
Another dye named 7-amino-actinomycin D (7-AAD, 2 in Figure 1.1) is also frequently 
utilized in these assays. The emission spectrum of 7-ADD is red-shifted compared to that 
of PI, reducing its spectral overlap with other green fluorophores in multi-color 
experiments.5 Recently, to more accurately distinguish living from dying or dead cells, a 
combination of three fluorescent reagents, including 4’-6-diamidino-2-phenylindole (DAPI, 
3), tetramethylrhodamine methyl ester (TMRM, 4) and fluorescein isothiocyanate(FITC, 
5)-conjugated Annexin V (Annex VFITC) have been used together (Structures are shown 
in Figure 1.1).6 Like PI and 7-AAD, DAPI binds to DNA and does not efficiently cross 
intact cell membranes, rendering it selective towards dead cells. TMRM is utilized to 
measure the mitochondrial membrane potential, an important indicator of the health of 
mitochondria, and TMRM accumulates specifically in active mitochondria of living cells. 
Annex VFITC is a fluorescent protein that binds to phosphatidylserine exposed on the outer 
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leaflet of the plasma membrane during early apoptosis. Through the use of these three 
dyes, cells can be sorted into populations of living cells (DAPI-/ TMRM+/ Annex VFITC-), 
apoptotic cells (DAPI-/ TMRM-/ Annex VFITC+), and necrotic cells (DAPI+/ TMRM-/ Annex 
VFITC+). Another frequently used dye is Hoechst 33342 (6 in Figure 1.1), which has been 
applied to stain and isolate the side population (SP) of cancer cells.7 These SP cells make 
up only a small percentage of cancer cells, but they feature upregulated ATP-binding 
cassette (ABC) transporter proteins. Hoechst 33342 is a known substrate of efflux pumps, 
making it an excellent tool to isolate SP cells.  
 
Figure 1.1. Examples of small-molecule fluorescent dyes used in cell sorting and flow 
cytometry. 
 
1.2.2 Identification of fluorescent probes used for cell sorting  
There are two major approaches to develop specific fluorescent dyes for use in 
cell sorting. One method starts with screening a library of structurally diverse fluorophores 
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against cells of interest and an isogenic counterpart, followed by a validation assay. This 
method has been termed the diversity-oriented fluorescence library approach (DOFLA)8. 
By screening a DOFL, many unique dyes have been discovered that identify specific cell 
types, including pluripotent stem cells,9 microglia,10 myocytes,11 and α and β cells from 
pancreatic islets.12, 13 One recent example of using DOFLA to establish a FACS method 
was the identification of a fluorescent probe named TiY (7 in Figure 1.2) that specifically 
labels tumor initiating cells (TICs) in non-small cell lung cancer.14 TICs are a 
subpopulation of cancer cells with high renewal capabilities that are associated with 
relapse and metastasis.15 To develop a TIC-specific fluorescent probe, thousands of 
compounds from a DOLF were screened against a pair of cell lines: TS32 cells with high 
tumor sphere forming ability and 32A cells in which the growth factor from media was 
removed to serve as an isogenic counterpart. Secondary screening was additionally 
performed using TS10 cells derived from another lung cancer patient, and LuEpi as 
normal lung epithelial cells. Less than 10 compounds out of thousands screened exhibited 
profound selectivity towards TS32 and TS10 over 32A and LuEpi cells. Among them, TiY 
was the most efficacious dye. Interestingly, it forms a covalently bond to vimentin, a 
biomarker protein found in the cytosol that is associated with formation of tumor spheroids.  
Another method to develop fluorescent probes for cell sorting is based on the 
rational design of a fluorescent substrate that can identify target cells that express a 
greater quantity of a specific enzyme compared to other cells. One classic example is 
BODIPY aminoacetaldehyde (BAAA, 8 in Figure 1.2), a substrate of aldehyde 
dehydrogenase 1 (ALDH1) that has been used to isolate cancer stem cells (CSC) that 
express ALDH1 at high levels. BAAA was constructed by conjugating the ALDH1 
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substrate aminoacetaldehyde with the fluorophore BODIPY. This green fluorescent 
substrate freely diffuses across cell membranes, but upon enzymatic reaction by ALDH1, 
it is converted into the corresponding acid, which is trapped in cells due to the generation 
of a negative charge. A high fluorescence intensity correlates to cells with high content of 
ALDH1, allowing their differentiation of cells with low levels of ALDH1. This method was 
initially reported for fractionation of primitive human hematopoietic stem cells (HSCs), a 
cell population with high fluorescence intensity and low light scattering, from blood 
samples by flow cytometry.16 After its commercialization by STEMCELL Technologies 
and rebranding as ALDEFLUOR, it has been applied to detect stem cells in many tissues, 
including those from prostate, lung, breast, skeletal muscle, and colon.17 Recently, to 
allow multicolor-based detection of CSCs with green fluorescent probes, a spectrally 
orthogonal red fluorescent substrate for ALDH named AldeRed 588-A (9 in Figure 1.2)18 
was synthesized by conjugating the aldehyde moiety to a red fluorophore BODIPY 
576/589. AldeRed 588-A exhibits specific uptake by cell lines expressing high levels of 
ALDH, K562 and L1210/cpa, compared to controls treated with the ALDH-inhibitor 
diethylaminobenzaldehyde (DEAB). AldeRed 588-A has been used to isolate human 
hematopoietic stem cells with high expression of ALDH from a heterogeneous mixture of 
blood cells, similar to ALDEFLUOR.  
 
Figure 1.2. Examples of fluorescent probes for cell sorting discovered by screening and 
rational design. 
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1.3 The use of fluorescent probes in screening 
Screening is a primary tool used to identify hit compounds with a desired biological 
activity in early-stage drug discovery. Advances in robotics have allowed the development 
of automated screening of large libraries of structurally diverse compounds, a method 
known as high throughput screening (HTS).19 The readout of this type of screening is 
often fluorescence from fluorescent dyes or proteins, such as direct measurements of 
fluorescence intensity, fluorescent polarization (FP), Förster resonance energy transfer 
(FRET), and other related signals.19, 20 These screening assays are usually performed in 
96, 384, or 1536-microwell plate formats, and instruments used for the detection of these 
signals include flow cytometers, plate readers, and high-throughput microscopes. The 
efficacy or potency of hit compounds can be represented by EC50 (concentration of 
compound needed to achieve 50% maximum efficacy), IC50 (concentration of compound 
needed to achieve 50% maximum inhibition), Kd (dissociation constant, ligand 
concentration needed to bind half of the protein) and Ki (dissociation constant of inhibitors, 
an experimental condition-independent parameter as compared to IC5021). The Ki can be 
derived from the IC50 by the Cheng-Prusoff equations shown in Figure 1.3, where the first 
equation is for inhibitor-enzyme interactions and the second one is for ligand-receptor 
interactions. A more general Cheng-Prusoff equation can be used where [A] is the 
concentration of agonist and [A50] is the agonist concentration causing 50% maximum 
response.22 
𝐾i =
IC50
1+[𝑆]/𝐾'
,𝐾i =
IC50
1+[𝐿]/𝐾*
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𝐾i =
IC50
(2 + ([𝐴]/[𝐴01])3)4/3 − 1
 
Figure 1.3. Cheng-Prusoff equations for analysis of competitive inhibition and binding. 
 
 
The sensitivity and performance of a screening assay is evaluated by its S:N (signal to 
noise), S:B (signal to background ratio), SW (signal window) and Z’ factor, which are 
defined by the equations shown in Figure 1.4. 
𝑆:𝑁 =
µ':; − µ'<3
𝜎'<3
	 , 𝑆: 𝐵 = 	
µ':;
µ'<3
 
𝑆𝑊 =
µ':; − µ'<3−3(𝜎':; + 𝜎ABC	)
𝜎':;
	 , 𝑍E = 1 −
3(𝜎':; + 𝜎ABC	)
|µ':; − µ'<3|
 
Figure 1.4. Equations used to determine assay sensitivity and performance (µ is the 
mean signal, σ is standard deviation of the signal). 
   
1.3.1 Screening using fluorescence intensity 
Fluorescence intensity provides one of the simplest methods for screening. 
Addition of test compounds is simply followed by measurement of fluorescence. This can 
be quantified by instruments such as flow cytometers, fluorescent plate readers, or 
microscopes. An example of a fluorescence-ON assay involves the identification of p-
glycoprotein (P-gp) inhibitors using the HTS-compatible probe calcein acetoxymethyl 
ester (Calcein AM, commercialized as the Vybrant Multidrug resistance assay, 10 in 
Figure 1.5).23 P-gp is an ABC transporter located on cellular plasma membranes that 
pumps out a variety of small molecule substrates. This transporter is frequently 
overexpressed by cancer cells and causes resistance to anti-cancer agents. Inhibition of 
P-gp provides a potential method to overcome resistance. Calcein, the hydrolyzed 
product of calcein AM, is a substrate of P-gp. It barely accumulates in cells expressing P-
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gp, resulting in very low fluorescence. However, in the presence of a P-gp inhibitor, 
calcein accumulates in the cytosol, leading to a large increase in fluorescence, which can 
be quantified to evaluate the efficacy of inhibitors.24 This assay has been applied to 
screen the Prestwick Chemical Library, and led to the discovery of three novel P-gp 
inhibitors.25 A fluorescent imaging-based HTS has also been used in this way to identify 
four new P-gp inhibitors from a kinase inhibitor library.26 
 
Figure 1.5. Principle of the Calcein AM assay of P-gp. 
 
Another class of fluorescent probes lose fluorescence upon addition of test 
compounds. An example of this type of assay involves a substrate tagged with a 
fluorophore and a nearby quencher. Because of the quencher, this probe is initially non-
fluorescent. Upon the cleavage by the enzyme, the dissociation of the quencher and 
fluorophore results in the emission of fluorescence. When an inhibitor is present, it can 
block the activity of the enzyme, causing an overall decrease of fluorescence compared 
to control. This reduction in fluorescence can be quantified as a function of concentration 
of the inhibitor to provide an IC50 value. Recently, a fluorogenic probe termed EP (11 in 
Figure 1.6) was synthesized and used to screen a fragment library containing 1460 
compounds. The goal was to identify potential inhibitors of ER aminopeptidase associated 
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with antigen processing (ERAAP), since downregulation of ERAAP leads to enhanced 
immune response to tumors. This EP probe is a modified substrate of ERAAP, where the 
N-terminus was linked to dinitrophenol (DNP) as a quencher and the C-terminus was 
tagged with the fluorophore BODIPY. The intact EP has low fluorescence due to 
quenching by the neighboring DNP, but upon addition of ERAAP, EP is hydrolyzed into 
two molecules, leading to emission of fluorescence from BODIPY. After a primary screen 
and validation, one fragment compound was found to be an irreversible inhibitor of 
ERAAP with the lowest IC50 (23 µM) reported to date.27 
  
Figure 1.6. Screening for ERAAP inhibitors based on a fluorogenic EP probe. 
 
Screening of fluorogenic probes of specific enzymes has not only been limited to 
peptide substrates but has also been applied to nucleic acids. One such example is OGR1 
(12 in Figure 1.7), a probe designed for determination of 8-oxoguanine glycosylase 1 
(OGG1) activity and screening of OGG1 inhibitors.28 OGG1 is the chief eukaryotic repair 
enzyme known to remove 8-oxoguanine by excising it from the sugar backbone of 
damaged double stranded DNA (dsDNA). 8-oxoguanine is also known to be a 
fluorescence quencher. To take advantage of this specific cleavage by OGG1 and the 
unique fluorescence quenching effect of 8-oxoguanine, the fluorescent nucleobase 
analogue tCo was installed in close proximity to the quencher 8-oxoguanine. Since 8-
oxoguanine decreases the fluorescence of tCo, very little fluorescence is detected when 
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the backbone is intact, whereas in the presence of OGG1, 8-oxoguanine is cleaved from 
DNA, causing a 60-fold increase in the fluorescence of tCo. After HTS of 25,975 
compounds followed by a validation assay, 22 compounds were confirmed as OGG1 
inhibitors. Among them, one hit, a tetrahydroquinoline sulfonamide derivative, was 
subjected to further structural optimization, leading to an inhibitor named SU0268, with 
59 nM IC50 value for OGG1.29 
 
Figure 1.7 Screening OGG1 inhibitors based on a fluorogenic OGR1 probe. 
 
However, measurement of fluorescence intensity can suffer from interference by 
compounds that exhibit intrinsic fluorescence and autofluorescence from biological 
samples, both of which can cause false positive results. To prevent these artifacts, a 
secondary screen of positive hits from the primary screen is usually be applied. Another 
solution involves using a far-red fluorescent probe for the readout to avoid spectral 
overlap with commonly used green or blue probes and biological autofluorescence.  
 
1.3.2 Screening by Förster resonance energy transfer (FRET) 
To minimize interference and increase the signal window, Förster resonance 
energy transfer (FRET) is another powerful technology for screening library compounds 
against proteins of interest. This fluorescence phenomenon was discovered by Theodor 
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Förster in 1948.30 FRET probes are usually composed of two fluorophores that are placed 
in close proximity to each other, with one serving as a donor and the other an acceptor. 
Upon excitation at the donor’s λmax, energy is transferred to the acceptor when it is in 
close proximity, resulting in emission by the acceptor instead of the donor. According to 
the PubChem BioAssay database, FRET-based screening has been used to identify more 
than 70 target proteins, including kinases, other enzymes and receptors. One method to 
design a FRET pair involves using the tryptophan residue from the protein of interest as 
the donor and a fluorescent ligand as the acceptor. This method is only possible if a 
tryptophan residue is part of or close to the binding site. For example, tryptophan can be 
paired with MANT-uracil (13 in Figure 1.8) at the binding site of cereblon to screen for 
inhibitors. MANT-uracil is a fluorescent ligand of the protein cereblon, a substrate of E3 
ubiquitin ligase and a major binding partner of thalidomide, a drug currently used to treat 
myeloma. Due to the close proximity of tryptophan to bound MANT-uracil in the binding 
pocket of cereblon, the energy from exciting tryptophan at 295 nm is transferred to the 
fluorescent ligand MANT-uracil, which emits fluorescence at 440 nm. MANT-uracil alone 
is excited to a much lesser extent by 295 nm light. The FRET signal increases with titration 
of MANT-uracil to cereblon in a dose dependent manner and yields a binding curve after 
blank correction. Inhibitors such as thalidomide compete away MANT-uracil, resulting in 
a dose-dependent decrease in FRET signal that can be quantified to calculate the IC50 
and Ki.31 
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Figure 1.8 A FRET-based assay designed for screening of cereblon inhibitors. 
 
1.3.3 Screening by fluorescence polarization 
After its first theoretical description in 1926, fluorescence polarization (FP) has 
provided a powerful tool for studying interactions between ligands of proteins and nucleic 
acids. More recent applications of FP to HTS during in the 1990s profoundly facilitated 
drug discovery.32 In this method, the fluorescent probe used is often called the tracer. 
When a fluorescent sample is excited by polarized light, emission intensity is collected 
parallel and perpendicular to the excitation light plane, represented as Fǁ	and F⊥. The 
polarization of the sample is defined as (Fǁ - F⊥)/(Fǁ + F⊥). As shown in Figure 1.9, when 
only a small molecule tracer is present, its fast rotation yields low polarization. However, 
when a macromolecule such as protein or nucleic acid is bound to the tracer, the resulting 
complex tumbles much slower and emits highly polarized light. Therefore, the change in 
polarization reflects the interaction of tracer with the macromolecule. Upon addition of a 
test compound as a competitor, the tracer is liberated, causing a decreased polarization 
value. This difference in polarization can be quantified and fit to provide a dose-response 
curve. The IC50 and Ki of the ligand can be determined from this data. Because FP is a 
homogenous assay that does not require a washing step, FP assays have been widely 
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applied in industry and academia to screen drug candidates against target 
macromolecules. According to the PubChem BioAssay database, common targets 
investigated with this method include kinases, ion channels, nuclear receptors, G-protein 
coupled receptors (GPCRs), epigenetic regulators, proteases, transcription factors, 
secreted proteins, and phosphodiesterases, . 
 
Figure 1.9. The principle of fluorescence polarization and its use in competition assays. 
  
If the ligand of interest itself emits detectable fluorescence, it may be directly used 
as tracer. However, in most cases, the tracer is synthesized by conjugating a ligand to a 
fluorophore. For instance, three BH3 peptides labeled with fluorescein were used to 
generate the tracers f-Bad (NLWAAQRYGRELRRMSDK(Fluor.)FVD), f-Bak 
(GQVGRQLAIIGDK(Fluor.)INR) and f-Bax ((Fluo.)QDASTKKLSECLKRIGDELDS).33 
These three BH3 peptides bind the target protein Bcl-XL, and FP assays with Bcl-XL were 
used to calculate the affinity and signal window. f-Bad was found to have the highest 
affinity (21 nM) and an acceptable signal window (120 mP). The stability of f-Bad over 
time and the effect of increasing amounts of DMSO was tested to confirm the robustness 
of this assay. A competitive assay was validated by comparing the affinity of published 
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ligands with ligands measured with this assay. The Z’ factor was found to range from 0.7 
to 0.88, indicating that this FP assay would be excellent for HTS. A library of 370,400 
compounds was screened by Abbott (now AbbVie), followed by a secondary assay 
involving affinity selection/mass spectrometry. From this study, 29 compounds with an 
affinity of better than 100 µM were obtained.34 Abbvie later utilized this approach to find 
a hit compound that inhibits myeloid cell leukemia 1 (MCL-1), a BCL-2 family protein 
associated with tumor initiation, at a single digit micromolar concentration.35 An academic 
group in Spain used this same method to screen the Prestwick Chemical Library of 880 
small molecules.36 They identified the antimalarial agent quinacrine as a weak inhibitor of 
Bcl-XL. 
The methods previously discussed primarily depend on the existence of a known 
substrate or ligand of a protein target. However, for enzymes that are not well-
characterized, it is challenging to design fluorescent probes based on a known substrate. 
To identify inhibitors of those enzymes, a fluorescence polarization technology for 
competitive activity-based protein profiling, named Fluopol-ABPP has been developed to 
address the problem.37 This technology uses a reactive fluorescent probe that covalently 
binds the active site of an enzyme of interest. Before addition of this probe to an enzyme 
pre-dispensed in multi-well plates, a test compound is pre-incubated with the enzyme. As 
shown in Figure 1.10A, inhibitors will block the active site of the enzyme and prevent the 
reaction of the covalent probe with the enzyme, leading to a low FP value. Inactive 
compounds unable to occupy the active site cause the enzyme to be labelled with 
fluorescent probe, resulting in high FP signal. Low FP signals indicate potent inhibitors. 
For example, a reactive fluorophosphate rhodamine probe (14 in Figure 1.10B) was used 
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to screen a library on 384-well plates to identify inhibitors of the cancer-associated 
retinoblastoma-binding protein-9 (RBBP9). This primary screening identified 35 hits out 
of 18,974 small molecules screened. After secondary proteomic assays, the alkaloid 
emetine was identified as a selective inhibitor of RBBP9 with an IC50 of 7.8 µM. This same 
method was applied to the discovery of thioltransferase glutathione S-transferase omega 
1(GSTO1) inhibitors, in which phenyl sulfonate rhodamine was used as the reactive 
fluorescent probe (15 in Figure 1.10B). Primary screening lead to 38 hits out of 2,000 
compounds, followed by a secondary selectivity assay that was used to identify a potent 
GSTO1 inhibitor (IC50 = 120 nM). Additionally, a rhodamine conjugated F-amidine (RFA, 
16 in Figure 1.10B) has been used to screen a 1,280-compound LOPAC library and 
identify ruthenium red (Ki of 17 µM) as the first inhibitor of apoenzyme protein arginine 
deiminases (PADs).38 
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Figure 1.10 Schematic description of fluopol-ABPP assay (A) and the structures of typical 
fluorescent probes used in this assay (B). 
 
1.4 Fluorescence-based imaging of subcellular compartments as a tool for drug 
discovery 
1.4.1 Mitochondria 
 Mitochondria are organelles found in most eukaryotic cells. Key functions of these 
organelles include ATP production via oxidative phosphorylation, calcium regulation, and 
lipid oxidation. These normal functions of mitochondria depend on the integrity of the 
structures of the outer membrane, the inner membrane, the intermembrane space 
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between the inner and outer membranes, and the cristae formed by folding of the inner 
membrane and the matrix within the inner membrane. The electron transport chain (ETC) 
located in this inner membrane is essential for the transfer electrons and protons during 
energy production. Pumping protons out of the matrix creates a proton gradient (ΔpH) 
and electric potential (ΔΨm) across the mitochondrial inner membrane, where the pH in 
the matrix is close to 8, generating a more positively charged environment in mitochondria. 
Compared to the plasma membrane potential (ΔΨm = -70 mV), the mitochondrial 
membrane potential is much larger (ΔΨm = -120 mV), especially in cancer cells (ΔΨm = -
180 mV), where increased oxidative phosphorylation is needed to meet the needs of rapid 
proliferation. These properties often cause lipophilic cations to accumulate in 
mitochondria to a greater extent than other organelles or the cytosol. This unique feature 
allows the development of fluorescent probes that target mitochondria. Three major 
scaffolds of mitochondria-targeted dyes are the rhodamines, carbocyanines and 
triphenylphosphonium (TPP), all of which contain lipophilic aromatic rings with positively 
charged amines or phosphates. 
 Ever since the first report of the ability of rhodamine 123 (17 in Figure 1.11) to 
selectively stain mitochondria of gerbil fibroma cells, rhodamines have been extensively 
studied as mitochondrial probes.39 Other rhodamine-based dyes that specifically label 
mitochondria are rhodamine 6G (18 in Figure 1.11),40 rhodamine B (19 in Figure 1.11),41 
and tetramethylrosamine (20 in Figure 1.11).42 Recently, the Peterson lab reported two 
novel hydrophobic rhodamines termed HRB and HR101 (21 and 22 in Figure 1.11) that 
are capable of labeling and visualizing mitochondrial dynamics in living C. elegans.43 All 
of the mitochondrial dyes previously described can be used to label living cells because 
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of their dependence on a functional mitochondrial membrane potential. Fixed (dead) cells 
that lack this potential do not selectively take up these dyes. To overcome this limitation, 
MitoTracker probes have been developed that stain active mitochondria but are retained 
after cellular fixation.44, 45 MitoTracker probes are structurally related to rhodamine, but 
include a reactive chloromethyl group on the southern benzene ring. This chloromethyl 
group is believed to react with thiol groups of cysteine residues and become covalently 
conjugated to mitochondrial proteins, resulting in retention even after cell fixation. 
MitoTracker Orange and MitoTracker Red (23 and 24 in Figure 1.11) emit red-shifted (> 
550 nm) fluorescence. Their spectral orthogonality to green and blue fluorophores makes 
them compatible with multicolor assays. To further increase selectivity and reduce 
background signals, reduced forms of MitoTracker probes have been synthesized.45 
These probes, including MitoTracker Orange CM-H2TMRos and MitoTracker Red CM-
H2XRos (25 and 26 in Figure 1.11), are non-fluorescent due to disruption of the 
conjugated ring system. They become fluorescent after penetration into active 
mitochondria, oxidation, and become trapped in these organelles. Like their oxidized form, 
they are suitable for analysis of fixed cells by confocal microscopy.46 Recently, silicon 
rhodamine, an analogue of rhodamine with silicon instead of oxygen in the xanthene 
middle ring, has gained  popularity due to its excellent brightness and high 
photostability.47 By screening a synthetic pool of ten analogues, a silicon rhodamine 
based fluorescent probe named SiR-Mito-8 (27 in Figure 1.11) was identified as a specific 
mitochondrial dye.48 Selectivity for mitochondria was shown to be associated with the 
hydrophobicity of the fluorophore, where more hydrophobic compounds (clogP > 5.5) 
tend to target mitochondria more effectively.  
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Figure 1.11. Rhodamines that selectively label mitochondria in living cells. 
 
 Most carbocyanine dyes with short alkyl chains, such as oxacarbocyanine DiOC6(3) 
and DiOC2(3) (28 and 29 in Figure 1.12), stain mitochondria of eukaryotic cells at low 
concentrations (~ 0.1 µg/ml).49 However, caution is needed when using these dyes at 
high concentrations because they are capable of staining other membranes such as those 
of the endoplasmic reticulum.50, 51 Indocarbocyanine DiIC1(5) (30 in Figure 1.12) is a far 
red probe that is sensitive to the mitochondrial membrane potential. It accumulates in 
active mitochondria, but it diffuses into the cytosol if depolarization occurs, providing a 
method to detect depolarization of these organelles. Thiacarbocyanine DiSC3(5) (31 in 
Figure 1.12) is another far red probe that accumulates in mitochondria. However, this 
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compound inhibits complex 1 of the electron transport chain (ETC) and increases 
generation of reactive oxygen species (ROS), making it very cytotoxic.52 Similar to other 
MitoTracker probes, MitoTracker Deep Red FM (32 in Figure 1.12)53-55 possess a 
chloromethyl group, making them compatible with both living and fixed cells. Due to its 
far red emission (λmax,em = 665 nm), MitoTracker Deep Red FM has been widely used in 
colocalization assays with other fluorophores or fluorescent proteins to determine 
selectivity for localization in mitochondria.54, 56-58 The green fluorophore MitoTracker Geen 
FM (33 in Figure 1.12) provides another mitochondrial dye that can be used in 
colocalization assays.59, 60 Unlike rhodamine 123, this green dye accumulates in 
mitochondria regardless of the membrane potential, and it is thought to selectively react 
with mitochondrial proteins.61 As a consequence, it has been used to determine the mass 
of mitochondria.62, 63 A dual emission probe termed JC-1 (34 in Figure 1.12) provides an 
approach to sensitively measure the mitochondrial membrane potential.64, 65 JC-1 exists 
as monomers at low concentrations and emits green fluorescence. However, at high 
concentrations it aggregates and emits red fluorescence. In healthy or polarized 
mitochondria, JC-1 accumulates at high concentrations and therefore predominantly 
forms J-aggregates that emit more red than green fluorescence. Upon depolarization of 
mitochondria, the J-aggregates diffuse away from mitochondria into the cytosol, leading 
to increasing amounts of monomers that emit only green fluorescence. The ratio of red to 
green fluorescence can be quantified and correlated with the mitochondrial membrane 
potential, but JC-1 is known to exhibit poor water solubility.66 More recently, JC-10, a 
similar potential-sensitive fluorescent probe, was developed to address this solubility 
issue.  
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Figure 1.12. Fluorescent carbocyanines that accumulate in mitochondria. 
 
 Triphenylphosphonium (TPP) has long been known as a mitochondria-targeting 
moiety.67 Conjugation of fluorophores with different emission profiles to TPP via a linker 
can be used to design mitochondria-targeted fluorescent probes. The coupling of TPP to 
BODIPY green, BODIPY red, or Cy5.5 has provided the TPP-based mitochondrial dyes 
TPP-Green, TPP-Red, and TPP-NIR (35, 36 and 37 in Figure 1.13).68 These probes can 
visualize mitochondria in cancer cells but are not particularly sensitive to the membrane 
potential. Attempts have been made to construct more potential-dependent probes by 
direct conjugation of TPP to BODIPY (38 in Figure 1.13). Although this probe is sensitive 
to the membrane potential, it only partially accumulates in mitochondria.69 Linking TPP to 
fluorescein via a decyl chain leads to MitoFluo (39 in Figure 1.13), a green fluorophore 
suitable for mitochondria imaging with protonophoric activity.70  
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Figure 1.13. TPP-based fluorescent probes for staining of mitochondria. 
 
 Other positively charged lipophilic fluorescent probes that accumulate in 
mitochondria include Pyronin Y,71 MitoBlue,72 and FPB (40, 41 and 42 in Figure 1.14).73  
 
Figure 1.14. Mitochondrial probes based on other fluorescent scaffolds. 
 
 
1.4.2 Microtubules as targets for the discovery of probes and drugs 
 Microtubules are a major component of the cytoskeleton of eukaryotic cells. They 
contribute to the structure and shape of cells. They also play crucial roles in mitosis and 
the transport of vesicles and organelles. Microtubules are long, hollow cylinders formed 
by tubulin proteins, composed of heterodimers of α-tubulin and β-tubulin. Many anti-
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cancer agents selectively bind to these proteins, and fluorescent analogues of anticancer 
agents can be used to image microtubules in cells.  
Most fluorescent probes of microtubules are based on fluorescent taxoids. Taxoids, 
compounds related to the anticancer drug Taxol (paclitaxel, 43 in Figure 1.15), stabilize 
microtubules by binding to β-tubulin. Some of the earliest fluorescent probes of 
microtubules comprise conjugates of the dyes fluorescein or Oregon Green linked to the 
7-OH of Taxol though L-Ala or β-Ala linkers and are termed Flutax-174 and Flutax-275 (44 
and 45 in Figure 1.15). Both of these dyes have been extensively studied as fluorescent 
taxoids for imaging of microtubules in cells and for studies of binding to tubulin. 
TubulinTracker Green (ThermoFisher Scientific, 46 in Figure 1.15) is an acetylated 
derivative of Flutax-2 that exhibits enhanced cellular permeability. After entering cells, this 
non-fluorescent probe requires hydrolysis by esterases to generate the fluorescent 
product Flutax-2. Hexaflutax (47 in Figure 1.15)76 is an analogue of Flutax-2 with a longer 
alkyl linker. This compound was previously used to establish the existence of a new 
accessible kinetic site on the microtubule surface that binds Taxol. Fchitax-3 (48 in Figure 
1.15)77 is a derivative of Flutax-2 that stains cellular microtubules, centrosomes, and 
mitotic spindles. Moreover, it exhibits increased potency against resistant cells that 
overexpress the efflux pump P-glycoprotein.   
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Figure 1.15. Structures of Taxol (paclitaxel) and fluorescent analogues. 
 
Replacement of the N-benzoyl group of the side chain on paclitaxel by a BODIPY 
propionyl substituent yields BODIPY FL Paclitaxel (49 in Figure 1.16), a fluorescent taxoid 
capable of producing fluorescent microtubules in solution that are stable for a week at 
room temperature.78 However, this compound is generally not suitable for imaging 
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microtubules in living cells. To overcome this limitation, a photoactivatable BODIPY 
paclitaxel (50 in Figure 1.16)79 was recently reported that attaches a boron-alkylated 
BODIPY to the 7-OH of Taxol via a β-Ala linker. The weakly fluorescent alkyl BODIPY 
can be converted into the strongly fluorescent methoxyl BODIPY upon irradiation. As 
expected, this BODIPY paclitaxel exhibits a 3-fold enhancement of fluorescence after 
photoactivation and can be used to visualize both in vitro assembled and intracellular 
microtubules using super-resolution microscopy. Another strategy to stain intracellular 
microtubules using the BODIPY fluorophore is to assemble the fluorescent probe (53 in 
Figure 1.16) in situ with a click reaction.80 The two reactants used are non-fluorescent 
Taxol-TCO and weakly fluorescent Tetrazine-BODIPY (51 and 52 in Figure 1.16). Trans-
cyclooctene (TCO) reacts rapidly with this tetrazine in water,81 and cells treated with 
Taxol-TCO followed by Tetrazine-BODIPY were reported to yield strong microtubule 
fluorescence, with minimal fluorescence background observed in controls only treated 
with the individual components. 
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Figure 1.16 Fluorescent BODIPY related taxoids. 
 
The silicon-rhodamine-based fluorescent taxoid SiR-tubulin (54 in Figure 1.17)82 
was constructed by connecting this fluorophore to the side-chain 3’-NH2 of Taxol. 
However, unlike BODIPY FL Paclitaxel, SiR-tubulin is able to image microtubules in living 
cells by super-resolution microscopy. The background signal of SiR-tubulin in cells is low, 
so a washing step was not required. This low background is a consequence of SiR-tubulin 
existing in equilibrium as a non-fluorescent spirolactone and a fluorescent zwitterion. 
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Initially, this compound predominately exists as the spirolactone. However, upon binding 
to the polar surface of microtubules, it shifts to the zwitterion, resulting in a 10-fold 
increase in fluorescence. The same group also developed the first larotaxel-based 
fluorescent probe of microtubules named 580CP-LTX (55 in Figure 1.17),83 which is 
synthesized by coupling carborhodamine 580CP to the 3’-position of larotaxel via an 8-
aminooctanoic acid linker.  
 
Figure 1.17. Other fluorescent probes for labeling of cellular microtubules. 
 
1.5 Outline of this dissertation 
 My research in the Peterson lab at KU Med. Chem. has focused on the study of 
fluorescent probes targeting proteins and cellular organelles and their application in 
cancer biology. Chapter 2 describes the synthesis and evaluation of a fluorescent 
analogue of Taxol that selectively targets microtubules and functions as a sensitive 
substrate of P-gp. Chapter 3 describes the identification of a fluorescent pyronin that 
enables rapid depolarization of mitochondrial membrane potential upon irradiation with 
visible blue light. 
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Chapter 2 - Fluorescent mimics of paclitaxel that selectively bind microtubules 
and sensitively detect efflux by P-glycoprotein 
 
2.1 Introduction 
Paclitaxel (Taxol, 2-1, structure shown in Figure 2-1) is a natural product isolated 
from the bark extract of yew tree Taxus brevifolia.1 It is been approved by FDA for 
treatment of various cancers, including ovarian, breast and lung cancers.2 Its widely 
acceptable mechanism of action for killing cancer involves binding of Taxol to the β 
subunit of the protein tubulin, which along with α-tubulin, forms microtubules in cells 
(Figure 2.1 shows a crystal structure of tubulin bound to the Taxol analogue Taxotere and 
assembly of microtubules).3 Hydrolysis of GTP to GDP provides a driving force for 
assembly of microtubules from dimers of alpha and beta tubulin.4, 5 These microtubules 
continuously participate in dynamic growth and shrinkage.6 Taxol stabilizes polymerized 
microtubules, inhibiting the these dynamics of tubulin polymerization.7 This can cause 
mitotic arrest and cell death by apoptosis.6, 8  
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Figure 2.1 Crystal structure of tubulin protein binding with Taxotere and dynamics of 
microtubules formed by tubulin 
 
However, in human patients, the anticancer activity of Taxol  is not fully consistent 
with an antimitotic mechanism of action.9, 10 In vivo, Taxol can shrink slow growing solid 
tumors, such as breast cancers that have a doubling time of approximately 147 days.10  
In these same patients, this drug has limited effect on rapidly dividing cells such as bone 
marrow myeloid progenitor cells, which double every 3 days. Thus, is unclear how Taxol 
selectively melts slow-growing tumors while sparing other rapidly dividing cells. This 
inconsistency has been termed the proliferation rate paradox.9  
To probe the mechanisms underlying the proliferation rate paradox, we 
hypothesized that a fluorescent mimic of Taxol that could be detected by confocal 
microscopy and quantified by flow cytometry could be beneficial. Many fluorescent 
taxoids have been reported, including commercially available Flutax-1, Flutax-2 and 
BODIPY-Taxol (structures are shown in Figure 2-2).11-25 Among them, Flutax-2 is one of 
the most extensively investigated fluorescent mimics. Structurally related compounds 
were first described by Nicolaou and co-workers.17 Flutax-2 is composed of Taxol linked 
at its 7-position to the bright green fluorophore Oregon Green (OG) with a β-alanine. The 
term Flutax-2 has also been used to describe related compounds with an L-Ala linker. 
These probes have been widely used to study the binding mode of Taxol to 
microtubules,11, 12 assessing efflux by P-glycoprotein,26 and analysis of tau-microtubule 
interactions.27 The BODIPY fluorophore has also been linked to Taxol.23-25 However, 
these BODIPY derivatives are not generally considered suitable for labeling intracellular 
tubulin in living cells. 
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The partitioning of a charged compound between organic and buffered aqueous 
solutions can be represented in log units and defined as LogDpH.28, 29 This can be a crucial 
physicochemical property for construction of fluorescent probes that penetrate cellular 
membranes. High experimental LogD values, and calculated cLogD values, are generally 
associated with higher permeability across lipid membranes. For the most drug-like 
fluorescent mimics of Taxol, the fluorophore should perturb the properties of Taxol to the 
lowest possible extent. In Flutax-2, OG exists as a polar dianion at physiological pH (pH 
= 7.4),30 causing a large increase of polarity of almost 1000 fold (cLogD7.4 = 0.0 for Flutax-
2 vs cLogD7.4 = 2.9 for Taxol). This loss of lipophilicity suggests that Flutax-2 will be less 
cell permeable than Taxol, and this high polarity might cause low cytotoxicity in cells 
compared with Taxol. Consequently, Flutax-2 does not closely mimic Taxol in 
physicochemical properties and cellular activity. 
To obtain a more drug-like fluorescent mimic of Taxol, a smaller and less polar 
fluorophore might be beneficial. For this application, we choose to incorporate the 
coumarin-derived fluorophore Pacific Blue (PB).31 Molly Lee of the Peterson laboratory 
developed a synthetic method to prepare PB on gram scale starting from inexpensive 
2,3,4,5-tetrafluorobenzoic acid.32 Additionally, PB can be excited at 405 nm with a violet 
laser found on many confocal microscopes and flow cytometers. As a new approach to 
create fluorescent mimics of Taxol, we designed three PB-Taxol analogues with different 
amino acid-derived linkers, PB-Gly-Taxol, PB-βAla-Taxol and PB-GABA-Taxol 
(structures shown in Figure 2-1). Because modification of the 7-OH of Taxol can preserve 
high affinity for microtubules,33 these three PB-Taxols were linked at this position. More 
importantly, the cLogD of a designed Taxol derivative linked to PB via the simplest amino 
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acid (glycine) bearing one methylene group (PB-Gly-Taxol, 2-5, cLogD7.4= 2.0) is close 
to the parent compound Taxol (cLogD7.4 = 2.9). The binding affinity, cytotoxicity, and efflux 
profiles of these compounds were evaluated by confocal laser scanning microscopy and 
flow cytometry. In these studies, the synthesis and determination of binding affinity were 
conducted by Dr. Molly Lee.  
 
 
Figure 2.2 Structures of Paclitaxel, commercially available fluorescent taxoids, and novel 
PB-Taxoids. 
 
2.2 Synthesis of PB-Taxols 
The PB-Taxols were prepared in four major steps as shown in Scheme 2.1. 
Protection of Taxol with TBSCl under basic conditions selectively modified the 2’-OH with 
TBS without reactivity at the 7-OH.34 After protection, Fmoc-amino acid linkers were 
conjugated to the 7-OH of TBS-protected Taxol (2-8) by classical EDC coupling to obtain 
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intermediates (2-9, 2-10, and 2-11). Cleavage of the Fmoc group with 20% piperidine in 
DMF, followed by reaction with the active ester PB-NHS provided the corresponding TBS-
protected PB-Taxols (2-12, 2-13, 2-14). The TBS group was deprotected using TBAF in 
THF to generate the desired PB-Taxols (2-5, 2-6, 2-7).  
 
Scheme 2.1 Synthesis of PB-Taxoids. Reagents and conditions: a) TBDMSCl, imidazole, 
DMF. b) Fmoc-aa-OH, EDC, DMAP, DCM/DMF. c) Piperidine, DMF. d) PB-NHS, DIEA, 
DMF. e) TBAF (1 M), THF. 
 
The most widely used fluorescent taxoid is Flutax-2. To compare novel taxoids 
with this compound, we synthesized Flutax-2 from intermediate 2-10 and Oregon Green 
NHS, followed by cleavage of the protecting group (Scheme 2.2). 
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Scheme 2.2 Synthesis of Flutax-2. Reagents and conditions: a) Piperidine, DMF. b) OG-
NHS, DIEA, DMF. c) TBAF, THF. 
 
 
2.3 Photophysical properties of PB-Taxoids 
To examine the photophysical properties of PB-Taxoids, absorption and emission 
spectra were obtained in 10% DMSO / PBS, with the inclusion of 0.5% Triton X-100 to 
limit aggregation. As shown in Figure 2.3, all three fluorescent taxoids exhibit similar 
absorption and emission spectra and can be readily excited with a violet laser at 405 nm, 
allowing imaging by confocal microscopy and analysis by flow cytometry. In contrast, 
Flutax-2 is red shifted compared to the PB-Taxoids and is best excited at 488 nm. In 
addition, the extinction coefficients of these compounds were determined to allow 
normalization of concentration by absorbance spectroscopy. Their extinction coefficients 
(ε = 24300 M-1cm-1 for PB-Gly-Taxol, ε = 23300 M-1cm-1 for PB-βΑla-Taxol, ε = 24100 M-
1cm-1 for PB-GABA-Taxol) are similar to the parent fluorophore PB (ε = 29500 M-1cm-1).32 
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Figure 2.3 Photophysical properties of fluorescent compounds. (A) Normalized 
absorbance (Abs., 10 µM) and emission (Em., 10 nM) spectra of PB-Gly-Taxol (2-5), PB-
βAla-Taxol (2-6), PB-GABA-Taxol (2-7), and Flutax-2 (2-3). (B) Determination of 
extinction coefficients of the PB-Taxoids.  
 
2.4 Determination of binding affinity for tubulin 
Computational docking of the PB-Taxoids, Flutax-2, and Taxol to a recent cryo-
EM structure of β-tubulin (PDB 3J6G)5 using Autodock Vina35 was used to compare 
possible modes of binding This modeling suggest that PB-Taxoids will bind tubulin 
similarly to Taxol. The fluorophore PB can potentially occupy a pocket close to the Taxol 
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binding site, suggesting it may favor binding (Figure 2.4). However, this approach was 
not able to readily predict differences in affinity of the different PB-Taxoids. 
 
Figure 2.4 Comparison of a published crystal structure of Taxol bound to β-tubulin with a 
model of PB-Gly-Taxol docked to the apo-protein. The core structure of PB-Gly-Taxol sits  
in the Taxol-binding pocket, whereas the PB side chain can fit into an adjacent pocket on 
the protein surface.  
 
To experimentally determine the binding affinities of PB-Taxoids for microtubules 
in vitro, we performed a fluorescence enhancement assay using crosslinked microtubules 
in aqueous GAB buffer (10 mM Phosphate, 1 mM EDTA, 1 mM GTP, 3.4 M glycerol, pH 
= 6.5). These studies revealed that PB-Gly-Taxol exhibited the lowest apparent Kd of 34 
± 6 nM, followed by PB-βAla-Taxol (Kd = 63 ± 8 nM) and PB-GABA-Taxol (Kd = 265 ± 54 
nM), indicating that the length of spacer between Taxol core structure and PB plays a 
crucial role in binding to microtubules. The shortest linker was found to be optimal, and 
the longer and more flexible spacers were detrimental to binding. Compared to the 
binding affinity of Flutax-2 (L-Ala, Kd = 14 nM) quantified by changes in fluorescence 
anisotropy,36 PB-Gly-Taxol was the most similar in affinity. 
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Figure 2.5 Determination of the binding affinities of PB-Taxoids (25 nM) to crosslinked 
microtubules by enhancement of fluorescence. Experiments were conducted in aqueous 
GAB buffer (pH 6.5). PB was excited at 405 nm and emitted photons were collected at 
and above 450 nm. 
 
2.5 Cytotoxicity of PB-Taxoids towards cancer cell lines 
Binding of Taxol to microtubules is known to be correlated with cytotoxicity in 
rapidly dividing cancer cells. Higher binding affinity usually aligns with higher cytotoxicity. 
To examine whether PB-Taxoids follow the same pattern, the toxicity of these compounds 
towards HeLa cervical carcinoma cells after 48 h were measured by flow cytometry. 
Propidium iodide (PI) was applied to stain dead cells and separate them from live ones. 
The count of live cells as a function of concentration was plotted in Prism 7 software to 
generate dose-response curves. The drug concentration where 50% of cells were dead 
was defined as the IC50. Compared with Taxol (IC50 = 7 nM), PB-Gly-Taxol (IC50 = 120 
nM) proved to be the most toxic of the three PB-Taxoids. PB-βAla-Taxol (IC50 = 1630 nM) 
and PB-GABA-Taxol (IC50 = 2090 nM) were found to be relatively non-toxic. These IC50 
values were correlated with the observed apparent Kd values. Interestingly, the toxicity of 
Flutax-2 (IC50 = 1750 nM) was low despite its high affinity for tubulin in vitro, suggesting 
that the OG fluorophore has a profound effect on the biological properties of Taxol. This 
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loss of toxicity from OG might be a result of low permeability and lower accumulation in 
cells. 
Taxol is known to be a substrate of P-glycoprotein (P-gp).37 This efflux pump, found 
on the plasma membrane, is mainly responsible for the elimination of xenobiotics.38 To 
examine whether PB-Taxols are similar to Taxol as efflux substrates, cells were co-
treated with verapamil, a known P-gp inhibitor.39 If PB-Taxols are substrates of P-gp, 
additional cellular uptake of PB-Taxols was predicted to be observed, potentially resulting 
in increased cellular fluorescence and cytotoxicity. After co-treatment with 25 µM of 
verapamil, a concentration that is nontoxic to HeLa cells (Figure 2.6), but sufficient 
enough to inhibit P-gp, we found that cytotoxic dose-response curves of PB-Taxols were 
shifted to the left compared to cells without verapamil (Figure 2.7). The IC50 values of 
Taxol, PB-Gly-Taxol, PB-βAla-Taxol and PB-GABA-Taxol decreased by approximately 2-
fold, 2-fold, 5-fold and 3.6-fold, respectively. More importantly, Flutax-2, a known P-gp 
substrate,26 exhibited the lowest cytotoxicity (IC50 = 1310 nM) in the presence of 
verapamil, suggesting it does not closely mimic Taxol in that respect. 
 
Figure 2.6 Analysis of cytotoxicity of verapamil in HeLa and HCT-15 cells over 48 h. 
Cellular viability was measured by flow cytometry. 
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Figure 2.7 Analysis of cytotoxicity in HeLa cells. Cells were treated with compounds in 
the absence (A) or presence (B) of verapamil (25 µM) for 48 h. Cell viability was measured 
by flow cytometry. 
 
The HeLa cell line is known to express low levels of P-gp40 compared to the HCT-
15 cell line. Consequently, the cytotoxicity of PB-Taxols in HCT-15 cells with or without 
verapamil was similarly evaluated. Similar to the trend observed in HeLa cells, PB-Gly-
Taxol (IC50 = 3760 nM) exhibited the greatest cytotoxicity compared to Taxol (IC50 = 120 
nM), followed by PB-βAla-Taxol (IC50 > 10000 nM) and PB-GABA-Taxol (IC50 > 20000 
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nM). The addition of 25 µM verapamil increased the cytotoxicity of Taxol, PB-Gly-Taxol, 
PB-βAla-Taxol and PB-GABA-Taxol by 40-fold, 42-fold, 34-fold and 27-fold, respectively.
 
Figure 2.8 Analysis of cytotoxicity in HCT15 cells. Cells were treated with compounds in 
the absence (A) or presence (B) of verapamil (25 µM) for 48 h. Cell viability was measured 
by flow cytometry. 
 
In contrast to Flutax-2 and the other PB-Taxols, PB-Gly-Taxol was found to exhibit 
the greatest toxicity and represent the closest fluorescent mimic of Taxol. Moreover, the 
effects of verapamil parallel the effect of this P-gp inhibitor on the toxicity of Taxol. For 
these reasons, we focused most of our further studies on this particular fluorescent probe. 
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2.6 Localization of PB-Taxoids in live cancer cells by confocal microscopy 
To visualize the localization of PB-Taxoids in live cells, confocal laser scanning 
microscopy was employed. These studies revealed that after treatment with PB-Gly-Taxol 
for 1 h, cellular fluorescence can be observed in a network of cytoplasmic filaments, 
consistent with association with microtubules. The addition of verapamil increased the 
brightness of this fluorescence in live HeLa cells in a dose-dependent manner (Figure 
2.9).  
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Figure 2.9 Dose-dependent effects of verapamil on the uptake of PB-Gly-Taxol in live 
HeLa cells. Images were taken by confocal laser scanning microscopy (Ex. 405 nm, Em. 
425-500 nm) after 1 h incubation at 37 °C with increasing concentration of verapamil (0, 
1, 10, 25, 100 µM, A to E). Scale bar = 25 microns. The structure of racemic verapamil is 
shown in F. 
 
To confirm the stained intracellular structrues are microtubules, a fluorescence 
colocalization assay was performed. Since the emission spectra of Flutax-2 and PB-Gly-
Taxol are mutually orthogonal, HeLa cells were co-treated with Flutax-2 and PB-Gly-Taxol. 
After incubation for 1 h, PB-Gly-Taxol colocalizes very well with Flutax-2 shown in Figure 
2.10, confirming binding to microtubules. However, PB-Gly-Taxol only stains microtubule, 
whereas Flutax-2 accumulates in other structures previously reported to be associated 
with the Golgi apparatus.16 
 
Figure 2.10 Confocal laser scanning and DIC microscopy of HeLa cells treated with PB-
Gly-Taxol (1 µM), Verapamil (25 µM) and Flutax-2 (5 µM) for 1 h at 37 °C. Scale bar = 25 
microns. 
 
2.7 PB-Gly-Taxol is a P-gp substrate as evidenced by confocal microscopy 
Overexpression of P-gp frequently confers resistance to the antiproliferative effect 
of Taxol.41 To further confirm that PB-Gly-Taxol is a P-gp substrate, we transfected PC-3 
cells that do not express P-gp42 with a plasmid (pHaMDR-EGFP)43 encoding P-gp fused 
to enhanced green fluorescent protein (EGFP). After 48 h, cells that were successfully 
transfected exhibited fluorescence (false colored red in Figure 2.11) on the plasma 
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membrane distinct from adjacent non-transfected cells that don’t express P-gp. After 
treatment with the spectrally orthogonal PB-Gly-Taxol for 1 h, the cells expressing P-gp 
exhibited little uptake of PB-Gly-Taxol (false colored green in Figure 2.11), whereas cells 
that did not express P-gp could be seen to strongly accumulate PB-Gly-Taxol on 
microtubules. This dramatic difference indicates that P-gp efficiently promotes efflux of 
PB-Gly-Taxol. Additionally, co-treatment with PB-Gly-Taxol and verapamil reversed this 
effect by inhibiting the efflux of PB-Gly-Taxol. This rescue of function depends on the 
concentration of verapamil. At 25 µM, cells with high expression of P-gp maintain some 
efflux of PB-Gly-Taxol. However, at 100 µM verapamil, most cells are stained with PB-
Gly-Taxol even cells that express high levels of P-gp. This evidence strongly supports the 
hypothesis that PB-Gly-Taxol is an efficient substrate of P-gp. 
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Figure 2.11 Confocal laser scanning and DIC micrographs of living PC3 cells transiently 
transfected with P-gp-EGFP and treated with PB-Gly-Taxol without (A) and with (B, C) 
verapamil. In panel B, the effects of lower and higher expression of P-gp in transfected 
cells treated with verapamil (25 µM) are highlighted. In panel C, treatment with a higher 
concentration of verapamil (100 µM) results in greater inhibition of efflux by P-gp. Scale 
bar = 25 microns. 
 
2.8 PB-Taxoids are highly sensitive substrates of P-gp 
To further investigate the sensitivity of PB-Gly-Taxol as a P-gp substrate, we 
compared this compound with the widely used P-gp substrate rhodamine 123 (Rho123).44 
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Rho123 is a green fluorophore that becomes localized in mitochondria. It additionally 
binds to a putative R site (named after Rho123) of P-gp. With addition of the P-gp inhibitor 
verapamil, Rho123 accumulate to a greater extent in mitochondria, resulting an increased 
fluorescence that can be detected by confocal microscopy and flow cytometry. After 
treatment of P-gp expressing HeLa cells with Rho123 or PB-Gly-Taxol for 1 h, we 
observed increased binding to mitochondria or microtubules by confocal microscopy upon 
addition of 25 µM verapamil. However, substantial differences were observed between 
these two probes. Using the same microscope settings (laser power and gain), the uptake 
of PB-Gly-Taxol was observed to increase dramatically whereas the change of cellular 
fluorescence with Rho123 was modest. A similar pattern was observed in P-gp-
overexpressing HCT15 cells (Figure 2.12).  
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Figure 2.12 Confocal laser scanning and DIC microscopy of HCT15 cells treated with P-
gp substrate Rho123 (A, C) or PB-Gly-Taxol (B) for 1 h 37°C. Scale bar = 25 microns. 
The structure of Rho123 is shown in D. 
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To quantify these changes of fluorescence intensity, we used flow cytometry to 
measure the fluorescence of each dye and calculate the fold change upon addition of 25 
µM or 100 µM verapamil. In HCT15 cells, the fluorescence of Rho123 increased by 3-fold 
with either 25 µM or 100 µM verapamil while the fluorescence of PB-Gly-Taxol increases 
by 7-fold with 25 µM and 15-fold with 100 µM verapamil. In HeLa cells, the fluorescence 
of Rho123 remains the same upon addition of 25 µM or 100 µM verapamil. We conclude 
that Rho123 is unable to detect P-gp at the low levels expressed by HeLa cells. In contrast, 
the fluorescence of PB-Gly-Taxol increases by 10-fold with 25 µM and 23-fold with 100 
µM verapamil, indicating it is a much more sensitive P-gp substrate than Rho123. 
 
Figure 2.13 Quantitative analysis of fluorescence changes of Rho123 (1 µM) or PB-Gly-
Taxol (1 µM) in HeLa cells (A) and HTC15 cells (B) upon addition of verapamil (0 µM, 25 
µM, 100 µM) for 1 h at 37 °C. 
 
2.9 Conclusions 
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Unlike Flutax-2, which exhibits low toxicity that does not closely mimic Taxol due 
to modification with the OG fluorophore, PB-Gly-Taxol recapitulates more of the tubulin 
binding, cytotoxicity, and efflux properties of parent drug Taxol. In brief, PB-Gly-Taxol 
binds microtubules with double digit nanomolar affinity, and it has the highest binding 
affinity among the three PB-Taxols studied. This high binding affinity data is correlated 
with enhanced cytotoxicity in both the HeLa and HCT-15 cancer cell lines. Additionally, in 
contrast to the commercially available Flutax-2, PB-Gly-Taxol stains microtubules in cells 
with high specificity as imaged by confocal microscopy. Similar to Taxol, PB-Gly-Taxol 
accumulates in a dose-dependent manner in HeLa cells upon addition of the P-gp 
inhibitor verapamil. This observation was supported by a transfection of PC3 cells with a 
plasmid encoding MDR-EGFP. Moreover, PB-Gly-Taxol is a much more sensitive than 
Rhodamine 123 as a P-gp substrate in cancer cell lines. In future studies, because PB-
Gly-Taxol represents a close mimic of many of the biological properties of Taxol, we 
hypothesize that it might provide as a novel tool the study proliferation rate paradox 
associated with this important anticancer drug. 
 
2.10 Experimental Section 
General experimental section. Chemicals were from Sigma Aldrich, Acros Organics, 
Alfa Aesar, Oakwood Chemical, or Chem-Impex International. 1H and 13C NMR spectra 
were acquired on an Avance AVIII 500 MHz instrument. Chemical shifts (δ) are reported 
in ppm referenced to CDCl3 (7.26 ppm for 1H and 77.2 ppm for 13C) or DMSO-d6 (2.50 
ppm for 1H, 39.5 ppm for 13C). 1H coupling constants (JHH, Hz) and 13C coupling constants 
(JCF, Hz) are reported as: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, m 
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= multiplet, dd = doublet of doublets, ddd = doublet of doublet of doublets, dq = doublet 
of quartets, dt = doublet of triplets, ddt = doublet of doublet of triplets), coupling constant, 
and integration. High Resolution Mass Spectra (HRMS) were obtained at the Mass 
Spectrometry Laboratory at the University of Kansas on a Micromass LCT Premier. Thin 
layer chromatography (TLC) used EMD aluminum-backed (0.20 mm) silica plates (60 F-
254). Flash chromatography used ICN silica gel (200-400 mesh). TLC plates were 
visualized with a UV lamp. Preparative HPLC was performed with an Agilent 1200 
instrument equipped with a Hamilton PRP-1 reverse phase column (250 mm length, 21.2 
mm ID, 7 μm particle size) with detection of absorbance at 215, 254, 370, and 488 nm. 
All non-aqueous reactions were carried out using flame- or oven-dried glassware under 
an atmosphere of dry argon or nitrogen. Tetrahydrofuran (THF), dichloromethane 
(CH2Cl2), and N,N-dimethylformamide (DMF) were purified via filtration through two 
columns of activated basic alumina under an atmosphere of argon using a solvent 
purification system from Pure Process Technology (GlassContour). Absorbance spectra 
were obtained using a semimicro (1.4 mL) UV quartz cuvette (Sigma-Aldrich, Z27667-7) 
on an Agilent 8452A diode array spectrometer. Molar extinction coefficients (ε), used to 
determine concentrations by absorbance, were measured in PBS (10 mM Na2HPO4, 137 
mM NaCl, 2.7 mM KCl, 1.8 mM KH2PO4, pH 7.4) containing 10% DMSO and 0.5% Triton 
X-100 and calculated from Beer’s Law plots of absorbance lmax versus concentration 
(Figure S1). Linear least squares fitting of the data (including a zero intercept) was used 
to determine the slope (ε). Fluorescence spectra were acquired using a SUPRASIL ultra-
micro quartz cuvette (PerkinElmer, B0631079) on a Perkin-Elmer LS55 Fluorescence 
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Spectrometer (10 nm slit width). Values for cLogDpH7.4 were calculated with MarvinView 
(v. 16.7.25.0, ChemAxon LogP method). 
 
Cell culture: HeLa cells, obtained from ATCC (CCL-2), were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM, Sigma D6429). PC-3 cells (a gift from Dr. Matthew Levy, 
Albert Einstein College of Medicine) were cultured in DMEM/Ham’s F-12 medium (Sigma 
8437). HCT-15 cells (ATCC CCL-225, a gift from Dr. Liang Xu, University of Kansas) were 
cultured in RPMI-1640 medium (Sigma R8758). Media was supplemented with fetal 
bovine serum (FBS, 10%), penicillin (100 units/mL), and streptomycin (100 µg/mL).  Cells 
were maintained in a humidified 5% CO2 incubator at 37 °C.  
 
Transient transfection of PC-3 cells with pHaMDR-EGFP: PC-3 cells in DMEM/Ham’s 
F-12 medium were seeded onto an 8-well cover glass slide (Ibidi µ-Slide, 300 µL, 20,000 
cells/well) and allowed to proliferate for 16 h at 37 °C. Plasmid pHaMDR-EGFP (2 µg, a 
gift from Dr. Michael M. Gottesman, National Cancer Institute) was incubated at 22 °C 
with the DNA transfection reagent X-tremeGENE HP (2 µL, Roche) in serum-free DMEM 
medium (200 µL). After 30 min, the DNA complex (20 µL) was added to each well. The 
cells were further incubated at 37 °C for 48 h. After transfection, the cells were washed 
with complete medium, further treated with probes, and imaged by confocal microscopy. 
 
Confocal microscopy: Cells were added to an 8-well cover glass slide (Ibidi µ-Slide, 300 
µL, 20,000 cells/well) and allowed to proliferate for 24 h prior to addition of compounds. 
Compounds in DMSO stock solutions were serially diluted 1,000-fold in complete medium 
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(final concentration of 0.1% DMSO) prior to addition to cells. Cells were treated with 
compounds at 37 °C for one hour before imaging with a Leica SPE2 confocal laser-
scanning microscope (63X oil-immersion objective). Taxol-PB analogues were excited 
with a 405 nm laser and emitted photons were collected from 425-500 nm. Flutax-2, 
EGFP, and rhodamine 123 were excited with a 488 nm laser and emitted photons were 
collected from 500-600 nm. 
 
Analysis of cytotoxicity: Cells were seeded on a 96-well plate in complete medium at 
8,000 cells / 200 µL per well 16 h prior to treatment. All compounds were serial diluted in 
DMSO and added to complete medium to achieve a 1:1000 dilution factor (0.1% DMSO 
in each well). The original media was removed from all wells by aspiration and replaced 
with the treatment media (200 µL) at the concentrations indicated. Plates were incubated 
for 48 h at 37 °C and cells were analyzed in triplicate. Following this incubation period, 
the media was aspirated and wells were washed with PBS (phosphate-buffered saline, 
pH 7.4). Wells were further treated with trypsin EDTA solution (50 µL) at 37 °C for 5 min 
(HeLa cells) or 10 min (HCT-15 cells) followed by complete medium (100 µL) containing 
propidium iodide (PI, 4.5 µM). The total cell-count for each well was determined by flow 
cytometry, using an Accuri C6 flow cytometer, and staining with propidium iodide was 
used to identify populations of live cells. Counts of viable cells for each treatment, 
determined in triplicate, were used to generate dose-response curves. These curves were 
fitted by non-linear regression with an inhibitor vs. response variable slope 4-parameter 
model (GraphPad Prism 7) to determine IC50 values. Based on curve fitting, standard 
errors for all cytotoxic IC50 values were < 5%. 
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Analysis of cellular efflux by flow cytometry:  Trypsinized HCT-15 or HeLa cells 
(200,000 cells/200 µL per Eppendorf tube) were incubated in suspension with PB-Gly-
Taxol (HeLa, 1 µM; HCT-15, 1 µM), Rho123 (HeLa, HCT-15, 1 µM), and either DMSO 
(0.2%) or verapamil (25 µM or 100 µM, 0.2% DMSO) for 1 h at 37 °C. After incubation, 
cells were centrifuged at 2000 rpm for 2 min. The supernatant was removed, cells were 
washed with cold PBS, and pelleted again by centrifugation. The PBS was removed, and 
cells were resuspended in cold PBS (2% BSA), and placed on ice prior to flow cytometry. 
Analysis was performed on a BD FACS Aria Fusion instrument equipped with 405 and 
488 nm lasers. 10,000 cells were counted for each sample and each condition was tested 
in triplicate. Photons emitted by PB-Gly-Taxol were collected after passing through a 
Pacific Blue filter (450 / 40 nm) and photons emitted by rhodamine 123 were collected 
after passing through a FITC filter (530 / 30 nm). Cell populations were gated based on 
untreated cells.  
 
Preparation of cross-linked microtubules: Following a previously published protocol15, 
microtubules were stabilized against disassembly for use in binding studies. Briefly, 
tubulin (50 µM, cytoskeleton Inc., cat# MT001-A, from bovine brain) in GAB buffer (10 
mM phosphate, 1 mM EDTA, 1 mM GTP, 3.4 M glycerol, pH 6.5) was incubated at 37 °C 
for 30 min to allow assembly of microtubules. Glutaraldehyde (20 mM) was added, and 
the solution was incubated at 37 °C for 10 min to achieve cross-linking. The reaction was 
quenched by the addition of NaBH4 (to 60 mM) on ice. 
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Determination of affinities of PB-Taxoids for tubulin by fluorescence enhancement: 
Fluorescence intensity data was acquired using a Corning 96-well solid black polystyrene 
microplate on a Packard Fusion Microplate Reader equipped with excitation (405 / 30 nm) 
and emission filters (450 nm LP) for Pacific Blue. The concentration of tubulin 
heterodimers was determined by absorbance at 280 nm in GAB buffer (pH 6.5) using e = 
115,000 M-1 cm-1. Different concentrations of cross-linked microtubules, chosen to span 
a range of at least 20% to 80% complexation, were incubated with fixed concentrations 
of 2-5, 2-6, 2-7 (25 nM) in GAB buffer (pH 6.5) at 22 °C with shaking for 1 h. These fixed 
probe concentrations were chosen to be below the predicted Kd values to assure 
equilibrium binding measurements. Measurements of fluorescence (Isample) were recorded 
for each sample. Average fluorescence (Imt) intensities of the background signal of 
microtubules alone were calculated by averaging three sample intensities for each 
concentration of tubulin in microtubules. Average fluorescence (If) intensities of the free 
ligand were calculated by averaging three sample intensities of the Pacific Blue probe in 
GAB. Background-subtracted fluorescence (I) signals were calculated as: 𝐼 = 	 𝐼I:'JKL −
𝐼'M 
The change in fluorescence intensity for each sample was calculated by subtracting the 
average (n=6) fluorescence of the free ligand (If). This change was plotted against the 
concentration of tubulin, and curve-fitting using a one-site specific binding model 
(GraphPad Prism 7) was used to calculate dissociation constants (Kd). Addition of Taxol 
(10 µM) as a competitor completely inhibited the increase in fluorescence of PB-Taxols 
upon binding, indicating a specific interaction of PB-Taxols at the Taxol-binding site (data 
not shown). 
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General synthesis procedure A: Synthesis of paclitaxel derivatives 2-9, 2-10, 2-11. 
Fmoc-amino acid derivatives (4 eq), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride (EDC, 4 eq.), and 4-dimethylaminopyridine (DMAP, 0.5 eq) were stirred in 
anhydrous CH2Cl2 : DMF (v/v = 2/1, 22 °C, 15 min). The TBS-protected paclitaxel 
derivative 2-8 was added, and the reaction mixture was stirred for 16 h. The mixture was 
diluted with CH2Cl2 (75–175 mL) and washed with saturated aqueous NH4Cl (50–100 mL 
x 1), water (25–50 mL x 1) and satd. aqueous NaCl (25–50 mL x 1). The organic layer 
was collected, dried over anhydrous Na2SO4 and purified by silica column 
chromatography (eluent: 97:3 CH2Cl2/MeOH).  
 
General synthesis procedure B: Synthesis of PB-Taxols (2-5, 2-6, 2-7). Tetra-N-
butylammonium fluoride in THF (TBAF, 1.0 M, 2 eq.) was added to a solution of 2-12, 2-
13, or 2-14 (1 eq.) in THF (0.5 mL) and stirred at 22 °C for 90 min. The reaction was 
concentrated under reduced pressure, the residue was dissolved in DMSO (1.5 mL), and 
the product purified by preparative RP-HPLC (gradient: H2O:CH3CN (9:1) to (0:100) with 
added TFA (0.1%) over 20 min; elution time = 16–17 min). Pure fractions were collected, 
combined, and solvent removed by lyophilization. 
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(2aR,4S,4aS,6R,9S,11S,12S,12bS)-9-(((2R,3S)-3-Benzamido-2-((tert-
butyldimethylsilyl)oxy)-3-phenylpropanoyl)oxy)-12-(benzoyloxy)-4,11-dihydroxy-
4a,8,13,13-tetramethyl-5-oxo-3,4,4a,5,6,9,10,11,12,12a-decahydro-1H-7,11-
methanocyclodeca[3,4]benzo[1,2-b]oxete-6,12b(2aH)-diyl diacetate (2-8). This 
compound was synthesized by modifying a previously reported (J. Am. Chem. Soc. 2007, 
129, 11653-11661) procedure. To a solution of paclitaxel (2-1, 500 mg, 0.59 mmol) in 
anhydrous DMF (2.1 mL) at 22 °C was added imidazole (208 mg, 3.06 mmol) and tert-
butyldimethylchlorosilane (542 mg, 3.61 mmol). After stirring for 16 h, the mixture was 
diluted with CH2Cl2 (175 mL) and washed with saturated aqueous NH4Cl (100 mL x 1), 
water (50 mL x 1) and satd. aqueous NaCl (50 mL x 1). The organic layer was collected, 
dried over anhydrous Na2SO4 and concentrated. The residue was triturated with hexane 
to afford 2-8 as a white solid (536 mg, 95%). 1H NMR (500 MHz, CDCl3) δ 8.18-8.10 (d, 
J = 8.0 Hz, 2H), 7.74 (d, J = 8.0 Hz, 2H), 7.64-7.45 (m, 4H), 7.45-7.36 (m, 4H), 7.33-7.30 
(m, 3H), 7.07 (d, J = 8.9 Hz, 1H), 6.34-6.24 (m, 2H), 5.78-5.63 (m, 2H), 5.04-4.92 (m, 1H), 
4.73-4.61 (m, 1H), 4.44 (dd, J = 11.0, 6.6 Hz, 1H), 4.33 (d, J = 8.5 Hz, 1H), 4.22 (d, J = 
8.5 Hz, 1H), 3.82 (d, J = 7.0 Hz, 1H), 2.63-2.52 (m, 4H), 2.48 (broad s, 1H), 2.40 (dd, J = 
15.3, 9.5 Hz, 1H), 2.23 (s, 3H), 2.17-2.06 (m, 1H), 1.97-1.84 (m, 4H), 1.77 (broad s, 1H), 
1.69 (s, 3H), 1.24 (s, 3H), 1.13 (s, 3H), 0.80 (s, 9H), –0.08 (s, 3H), –0.29 (s, 3H); 13C NMR 
(126 MHz, CDCl3) δ 203.9, 171.5, 171.4, 170.3, 167.2, 167.0, 142.6, 138.4, 134.2, 133.8, 
133.0, 132.0, 130.4, 129.2, 128.93, 128.89, 128.86, 128.1, 127.1, 126.6, 84.6, 81.3, 79.3, 
76.6, 75.7, 75.3, 75.2, 72.3, 71.5, 58.6, 55.8, 45.6, 43.4, 35.9, 35.7, 26.9, 25.7, 23.2, 22.4, 
21.00, 18.3, 15.1, 9.8, –5.1, –5.7; HRMS (ESI-) m/z 990.4047 (M-H+, C53H65NO14SiNa 
requires 990.4072). 
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(2aR,4S,4aS,6R,9S,11S,12S,12bS)-4-(((((9H-Fluoren-9-
yl)methoxy)carbonyl)glycyl)oxy)-9-(((2R,3S)-3-benzamido-2-((tert-
butyldimethylsilyl)oxy)-3-phenylpropanoyl)oxy)-12-(benzoyloxy)-11-hydroxy-
4a,8,13,13-tetramethyl-5-oxo-3,4,4a,5,6,9,10,11,12,12a-decahydro-1H-7,11-
methanocyclodeca[3,4]benzo[1,2-b]oxete-6,12b(2aH)-diyl diacetate (2-9). Following 
general procedure A, Fmoc-Gly-OH (119 mg, 0.4 mmol) and 2-8 (97 mg, 0.1 mmol) 
yielded 2-9 (43 mg, 35%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 8.16 (m, 2H), 
7.84-7.74 (m, 4H), 7.71-7.61 (m, 3H), 7.60-7.30 (m, 16H), 7.11 (d, J = 11.0 Hz, 1H), 6.29 
(t, J = 11.0 Hz, 1H), 6.23 (s, 1H), 5.84-5.68 (m, 3H), 5.54 (m, 1H), 5.07-4.97 (m, 1H), 4.70 
(d, J = 2.5 Hz, 1H), 4.48-4.35 (m, 3H), 4.30 (t, J = 9.5 Hz, 1H), 4.23 (d, J = 10.5 Hz, 1H), 
4.17-4.08 (m, 1H), 3.99 (d, J = 9.0 Hz, 1H), 3.91-3.81 (m, 1H), 2.71-2.52 (m, 4H), 2.51-
2.38 (m, 1H), 2.32-3.11 (m, 4H), 2.00 (s, 3H), 1.96-1.89 (m, 1H), 1.85 (s, 3H), 1.25 (s, 
3H), 1.19 (s, 3H), 0.83 (s, 9H), –0.01 (s, 3H), –0.27 (s, 3H); 13C NMR (126 MHz, CDCl3) 
δ 202.0, 171.6, 170.1, 170.0, 169.8, 167.2, 167.0, 156.9, 144.2, 144.0, 141.4, 141.38, 
141.35, 138.3, 134.2, 133.9, 132.4, 132.0, 130.4, 129.1, 128.94, 128.91, 128.2, 127.79, 
127.78, 127.2, 127.1, 126.5, 125.5, 125.4, 120.1, 84.0, 81.1, 78.7, 76.5, 75.8, 75.2, 74.5, 
72.1, 71.5, 67.4, 56.2, 55.8, 47.3, 47.0, 43.5, 43.2, 35.7, 33.4, 26.5, 25.7, 23.1, 21.5, 21.1, 
18.3, 14.8, 11.0, –5.1, –5.7; HRMS (ESI+) m/z 1269.4939 (M+Na+, C70H78N2O17SiNa 
requires 1269.4968). 
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(2aR,4S,4aS,6R,9S,11S,12S,12bS)-9-(((2R,3S)-3-Benzamido-2-((tert-
butyldimethylsilyl)oxy)-3-phenylpropanoyl)oxy)-12-(benzoyloxy)-4-(((6,8-difluoro-
7-hydroxy-2-oxo-2H-chromene-3-carbonyl)glycyl)oxy)-11-hydroxy-4a,8,13,13-
tetramethyl-5-oxo-3,4,4a,5,6,9,10,11,12,12a-decahydro-1H-7,11-
methanocyclodeca[3,4]benzo[1,2-b]oxete-6,12b(2aH)-diyl diacetate (2-12). To a 
solution of piperidine (20%) in DMF (2 mL) was added 2-9 (14 mg, 0.011 mmol). The 
mixture was stirred at 22 °C for 10 min followed by complete removal of piperidine under 
reduced pressure. To this crude intermediate in DMF (0.5 mL) was added Pacific Blue-
NHS ester (5 mg, 0.015 mmol), and DIEA (6 µL, 0.034 mmol). After stirring for 16 h, the 
reaction was concentrated under reduced pressure. The crude product was dissolved in 
DMSO (2 mL) and purified by preparative reverse phase HPLC (gradient: 90/10 
H2O/MeCN to 100% MeCN over 20 min with 0.1% TFA added; retention time = 19 min) 
to yield 2-12 (12 mg, 85%) as a yellow solid. 1H NMR (500 MHz, CDCl3) δ 9.07 (t, J = 6.0 
Hz, 1H), 8.71 (d, J = 1.3 Hz, 1H), 8.13-8.06 (m, 2H), 7.78-7.71 (m, 2H), 7.61-7.28 (m, 
10H), 7.14 (d, J = 9.0 Hz, 1H), 7.09 (dd, J = 9.3, 1.3 Hz, 1H), 6.28 (t, J = 9.2 Hz, 1H), 6.20 
(s, 1H), 5.81-5.62 (m, 3H), 5.02-4.98 (m, 1H), 4.67 (d, J = 2.1 Hz, 1H), 4.40-4.26 (m, 2H), 
4.24-4.14 (m, 2H), 3.96 (d, J = 7.0 Hz, 1H), 2.73-2.52 (m, 4H), 2.40 (dd, J = 15.3, 9.4 Hz, 
1H), 2.32-2.15 (m, 4H), 2.00-1.85 (m, 4H), 1.79 (s, 3H), 1.58 (broad s, 1H), 1.23 (s, 3H), 
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1.14 (s, 3H), 0.78 (s, 9H), –0.04 (s, 3H), –0.31 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 
201.8, 171.6, 170.2, 170.1, 169.2, 167.8, 166.9, 161.9, 159.6, 148.9 (dd, J = 243.9, 3.5 
Hz), 147.8, 141.4, 140.9 (d, J = 10.7 Hz), 139.6 (m), 138.8 (dd, J = 244.4, 5.0 Hz), 138.1, 
138.0, 134.0, 133.9, 132.6, 132.1, 130.3, 129.1, 129.0, 128.89, 128.87, 128.2, 127.1, 
126.5, 116.5, 110.3 (d, J = 9.1 Hz), 109.9 (dd, J = 20.0, 2.4 Hz), 84.1, 81.1, 78.7, 76.5, 
75.6, 75.1, 74.5, 72.6, 71.5, 56.0, 55.9, 47.0, 43.5, 42.1, 35.6, 33.3, 26.6, 25.6, 23.1, 21.6, 
21.0, 18.3, 14.8, 11.0, –5.1, –5.9, HRMS (ESI+) m/z 1271.4191 (M+Na+, 
C65H70N2O19SiNa requires 1271.4208). 
  
(2aR,4S,4aS,6R,9S,11S,12S,12bS)-9-(((2R,3S)-3-Benzamido-2-hydroxy-3-
phenylpropanoyl)oxy)-12-(benzoyloxy)-4-(((6,8-difluoro-7-hydroxy-2-oxo-2H-
chromene-3-carbonyl)glycyl)oxy)-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-
3,4,4a,5,6,9,10,11,12,12a-decahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-
b]oxete-6,12b(2aH)-diyl diacetate (PB-Gly-Taxol, 2-5). Following general procedure B, 
2-12 (10 mg, 0.008 mmol) yielded compound 1 (6 mg, 67%) as a yellow solid. 1H NMR 
(500 MHz, CDCl3) δ 9.09 (t, J = 6.0 Hz, 1H), 8.79 (d, J = 1.0 Hz, 1H), 8.16-8.07 (m, 2H), 
7.82-7.75 (m, 2H), 7.68-7.60 (m, 1H), 7.56-7.34 (m, 10H), 7.23 (dd, J = 9.0, 2.0 Hz, 1H), 
7.12 (d, J = 9.0 Hz, 1H), 6.23-6.14 (m, 2H), 5.82 (dd, J = 9.0, 2.5 Hz, 1H), 5.69-5.61 (m, 
2H), 5.00-4.94 (m, 1H), 4.82 (d, J = 2.5 Hz, 1H), 4.40-4.28 (m, 2H), 4.24-4.13 (m, 2H), 
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3.95-3.88 (d, J = 7.0 Hz, 1H), 2.72-2.58 (m, 1H), 2.44-2.29 (m, 4H), 2.27 (s, 3H), 1.97-
1.88 (m, 2H), 1.82 (s, 3H), 1.80 (s, 3H), 1.24 (s, 3H), 1.17 (s, 3H);  HRMS (ESI-) m/z 
1133.3340 (M-H+, C59H55F2N2O19 requires 1133.3367). 
 
Figure 2.12 Analytical HPLC profile of PB-Gly-Taxol (2-5) after preparative HPLC. 
Retention time = 18.0 min monitored by UV absorbance at 254 nm. Purity >96% by HPLC.  
 
(2aR,4S,4aS,6R,9S,11S,12S,12bS)-4-((3-((((9H-Fluoren-
9yl)methoxy)carbonyl)amino)propanoyl) 
oxy)-9-(((2R,3S)-3-benzamido-2-((tert-butyldimethylsilyl)oxy)-3-
phenylpropanoyl)oxy)-12 (benzoyloxy)-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-
3,4,4a,5,6,9,10,11,12,12a-decahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-
b]oxete-6,12b(2aH)-diyl diacetate (2-10). Following general procedure A, Fmoc-b-Ala-
OH (643 mg, 2.06 mmol) and 2-8 (500 mg, 0.52 mmol) yielded 2-10 (440 mg, 68%) as a 
white solid. 1H NMR (500 MHz, CDCl3) δ 8.17-8.11 (m, 2H), 7.79-7.73 (m, 4H), 7.68-7.57 
(m, 3H), 7.57-7.26 (m, 15H), 7.08 (d, J = 8.5 Hz, 1H), 6.31 (s, 1H), 6.27 (t, J = 9.5 Hz, 
1H), 5.83 (t, J = 6.0 Hz, 1H),  5.77-5.59 (m, 3H), 4.98 (dd, J = 9.6, 2.0 Hz, 1H), 4.68 (d, J 
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= 2.2 Hz, 1H), 4.45-4.30 (m, 3H), 4.25-4.18 (m, 2H), 3.99 (d, J = 6.8 Hz, 1H), 3.58-3.42 
(m, 2H), 2.64-2.50 (m, 6H), 2.44 (dd, J = 15.2, 9.4 Hz, 1H), 2.21-2.12 (m, 1H), 2.10 (s, 
3H), 1.99 (s, 3H), 1.93-1.85 (m, 1H), 1.84 (s, 3H), 1.23 (s, 3H), 1.18 (s, 3H), 0.80 (s, 9H), 
–0.03 (s, 3H), –0.30 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 202.4, 171.6, 171.4, 170.1, 
169.8, 167.1, 156.6, 144.20, 144.19, 141.4, 141.3, 138.4, 134.2, 134.0, 132.7, 132.0, 
130.4, 129.1, 129.0, 128.9, 128.1, 127.8, 127.2, 127.1, 126.5, 125.3, 120.0, 84.0, 81.0, 
78.8, 76.5, 75.5, 75.2, 74.6, 71.7, 71.4, 66.7, 56.2, 55.8, 47.4, 46.8, 43.4, 36.2, 35.8, 34.4, 
33.6, 26.5, 25.7, 23.2, 21.6, 20.9, 18.3, 14.8, 11.1, –5.0, –5.7; HRMS (ESI+) m/z 
1283.5148 (M+Na+, C71H80N2O17SiNa requires 1283.5124). 
 
(2aR,4S,4aS,6R,9S,11S,12S,12bS)-9-(((2R,3S)-3-Benzamido-2-((tert-
butyldimethylsilyl)oxy)-3-phenylpropanoyl)oxy)-12-(benzoyloxy)-4-((3-(6,8-
difluoro-7-hydroxy-2-oxo-2H-chromene-3-carboxamido)propanoyl)oxy)-11-
hydroxy-4a,8,13,13-tetramethyl-5-oxo-3,4,4a,5,6,9,10,11,12,12a -decahydro-1H-
7,11-methanocyclodeca[3,4]benzo[1,2-b]oxete-6,12b(2aH)-diyl diacetate (2-13). 2-
10 (100 mg, 0.079 mmol)  was stirred for 10 min at 22 °C in piperidine / DMF (1:5, 2 mL). 
Piperidine was completely removed under reduced pressure, and Pacific Blue-NHS ester 
(32 mg, 0.094 mmol) and DIEA (69 µL, 0.397 mmol) in DMF (2 mL) were added. After 
stirring for 16 h, the reaction was concentrated under reduced pressure. Silica 
chromatography (eluent: 290:9:1 CH2Cl2/MeOH/AcOH) yielded 2-13 (80 mg, 80%) as a 
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yellow solid. 1H NMR (500 MHz, CDCl3) δ 8.94 (t, J = 6.0 Hz, 1H), 8.71 (d, J = 1.3 Hz, 
1H), 8.16-8.08 (m, 2H), 7.79-7.72 (m, 2H), 7.61-7.54 (m, 1H), 7.54-7.28 (m, 10H), 7.17-
7.09 (m, 2H), 6.28 (t, J = 9.5 Hz, 1H), 6.25 (s, 1H), 5.76-5.64 (m, 3H), 5.03-4.96 (m, 1H), 
4.68 (d, J = 2.0 Hz, 1H), 4.35 (d, J = 8.5 Hz, 1H), 4.21 (d, J = 8.5 Hz, 1H), 3.98 (d, J = 6.5 
Hz, 1H), 3.80-3.63 (m, 2H), 2.73-2.60 (m, 3H), 2.59 (s, 3H), 2.42 (dd, J = 15.3, 9.4 Hz, 
1H), 2.20-2.15 (m, 1H), 2.14 (s, 3H), 1.98 (s, 3H), 1.96-1.88 (m, 1H), 1.83 (s, 3H), 1.76 
(broad s, 1H), 1.30-1.23 (m, 1H), 1.22 (s, 3H), 1.16 (s, 3H), 0.80 (s, 9H), –0.02 (s, 3H), –
0.31 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 202.1, 171.6, 171.2, 170.1, 169.3, 167.5, 
167.0, 161.5, 159.9, 149.1 (dd, J = 243.81, 3.78 Hz), 147.5, 141.1, 140.8 (d, J = 8.82 Hz), 
139.8(m), 139.2(dd, J = 243.18, 8.82 Hz), 138.2, 134.1, 133.9, 132.7, 132.1, 130.3, 129.1, 
128.94, 128.89, 128.1, 127.2, 126.5, 116.8, 110.3 (d, J = 9.35 Hz), 109.8 (dd, J = 20.16, 
3.38 Hz), 84.2, 81.1, 78.8, 76.6, 75.4, 75.2, 74.6, 71.8, 71.4, 56.1, 55.9, 47.0, 43.5, 35.7, 
35.4, 34.1, 33.4, 26.5, 25.7, 23.2, 21.5, 20.9, 18.3, 14.8, 11.1, –5.0, –5.7; HRMS (ESI+) 
m/z 1263.4574 (M+H+, C66H73F2N2O19Si  requires 1263.4545). 
 
(2aR,4S,4aS,6R,9S,11S,12S,12bS)-9-(((2R,3S)-3-Benzamido-2-hydroxy-3-
phenylpropanoyl)oxy)-12-(benzoyloxy)-4-((3-(6,8-difluoro-7-hydroxy-2-oxo-2H-
chromene-3-carboxamido)propanoyl) oxy)-11-hydroxy-4a,8,13,13-tetramethyl-5-
oxo-3,4,4a,5,6,9,10,11,12,12a-decahydro-1H-7,11-
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methanocyclodeca[3,4]benzo[1,2-b]oxete-6,12b(2aH)-diyl diacetate (PB-βAla-
Taxol, 2-6). To a solution of 2-13 (50 mg, 0.040 mmol) in anhydrous THF (1 mL) at 22 °C 
was added a solution of TBAF in THF (1.0 M, 84 µL, 0.084 mmol). After stirring for 90 
min, the mixture was concentrated and purified by silica column chromatography (1:9:290 
AcOH/MeOH/DCM) to afford 2-6 as a yellow solid (44 mg, 97%). 1H NMR (500 MHz, 
CDCl3) δ 9.03 (t, J = 6.0 Hz, 1H), 8.76 (s, 1H), 8.10 (d, J = 7.0 Hz, 2H), 7.77 (d, J = 7.0 
Hz, 2H), 7.65-7.58 (m, 1H), 7.55-7.30 (m, 10H), 7.21 (dd, J = 9.1, 1.7 Hz, 2H), 6.21-6.13 
(m, 2H), 5.80 (dd, J = 8.5, 2.0 Hz, 1H), 5.66 (d, J = 7.0 Hz, 1H), 5.61 (dd, J = 10.5, 7.0 
Hz, 1H), 4.95 (dd, J = 9.3, 1.8 Hz, 1H), 4.81 (d, J = 2.5 Hz, 1H), 4.32 (d, J = 8.5 Hz, 1H), 
4.19 (d, J = 8.5 Hz, 1H), 3.91 (d, J = 7.0 Hz, 1H), 3.81-3.61 (m, 2H), 2.75-2.66 (m, 1H), 
2.66-2.56 (m, 2H) 2.37 (s, 3H), 2.35-2.27 (m, 2H)  2.12 (s, 3H), 1.94-1.80 (m, 2H), 1.86-
1.76 (m, 6H), 1.20 (s, 3H), 1.15 (s, 3H); HRMS (ESI-) m/z 1147.3541 (M-H+, 
C60H57F2N2O19  requires 1147.3524). 
 
 
Figure 2.13 Analytical HPLC profile of PB-b-Ala-Taxol (2-6) after preparative HPLC. 
Retention time = 17.9 min monitored by UV absorbance at 254 nm. Purity >98% by HPLC.   
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(2aR,4S,4aS,6R,9S,11S,12S,12bS)-4-((4-((((9H-Fluoren-9-yl)methoxy)carbonyl)- 
amino)butanoyl)oxy)-9-(((2R,3S)-3-benzamido-2-((tert-butyldimethylsilyl)oxy)-3-
phenylpropanoyl)oxy)-12-(benzoyloxy)-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-
3,4,4a,5,6,9,10,11,12,12a-decahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-
b]oxete-6,12b(2aH)-diyl diacetate (2-11). Following general procedure A, 4-(Fmoc-
amino)butyric acid (130 mg, 0.4 mmol) and 2-8 (97 mg, 0.1 mmol) yielded 2-11 (100 mg, 
79%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 8.17-8.10 (m, 2H), 7.80-7.72 (m, 4H), 
7.65-7.57 (m, 3H), 7.59-7.47 (m, 3H), 7.46-7.29 (m, 11H), 7.08 (d, J = 9.0 Hz, 1H), 6.32-
6.20 (m, 2H), 5.82-5.66 (m, 3H), 5.59 (dd, J = 10.6, 7.0 Hz, 1H), 4.98 (dd, J = 9.7, 2.0 Hz, 
1H), 4.67 (d, J = 2.0 Hz, 2H), 4.46-4.40 (m, 2H), 4.38-4.32 (m, 1H), 4.26-4.16 (m, 2H), 
3.96 (d, J = 6.8 Hz, 1H), 3.42-3.12 (m, 2H), 2.67-2.53 (m, 4H), 2.49-2.39 (m, 2H), 2.32-
2.23 (m, 1H), 2.22-2.12 (m, 1H), 2.06 (s, 3H), 1.97 (s, 3H), 1.87-1.80 (m, 4H), 1.75-1.69 
(m, 3H), 1.22 (s, 3H), 1.17 (s, 3H), 0.80 (s, 9H), –0.03 (s, 3H), –0.30 (s, 3H);  13C NMR 
(126 MHz, CDCl3) δ 201.9, 172.4, 171.6, 170.3, 170.0, 167.2, 167.0, 156.7, 144.2, 141.5, 
141.4, 141.2, 138.3, 134.2, 133.9, 132.6, 132.0, 130.4, 129.1, 128.94, 128.90, 128.1, 
127.8, 127.7, 127.19, 127.16, 127.13, 126.5, 125.2, 125.1, 120.1, 84.1, 81.1, 78.7, 76.5, 
75.6, 75.2, 74.6, 71.6, 71.4, 66.3, 56.2, 55.8, 47.5, 47.0, 43.5, 39.4, 35.7, 33.5, 30.0, 26.5, 
25.7, 23.8, 23.2, 21.5, 20.9, 18.3, 14.8, 11.1, –5.0, –5.7.; HRMS (ESI+) m/z 1297.5265 
(M+Na+, C72H82N2O17SiNa requires 1297.5281). 
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(2aR,4S,4aS,6R,9S,11S,12S,12bS)-9-(((2R,3S)-3-Benzamido-2-((tert-
butyldimethylsilyl)oxy)-3-phenylpropanoyl)oxy)-12-(benzoyloxy)-4-((4-(6,8-
difluoro-7-hydroxy-2-oxo-2H-chromene-3-carboxamido)butanoyl)oxy)-11-hydroxy-
4a,8,13,13-tetramethyl-5-oxo-3,4,4a,5,6,9,10,11,12,12a-decahydro-1H-7,11-
methanocyclodeca[3,4]benzo[1,2-b]oxete-6,12b(2aH)-diyl diacetate (2-14). To a 
solution of piperidine (20%) in DMF (1 mL) was added 2-11 (30 mg, 0.024 mmol). The 
mixture was stirred at 22 °C for 10 min followed by complete removal of piperidine under 
reduced pressure. To this crude intermediate in DMF (1 mL) was added Pacific Blue-NHS 
ester, prepared as previously described (10 mg, 0.028 mmol), and DIEA (12 µL, 0.069 
mmol). After stirring for 16 h, the reaction was concentrated under reduced pressure. The 
crude product was dissolved in DMSO (2 mL) and purified by preparative reverse phase 
HPLC (gradient: 90/10 H2O/MeCN to 100% MeCN over 20 min with 0.1% TFA added; 
retention time = 19 min) to yield 2-14 (26 mg, 87%) as a yellow solid. 1H NMR (500 MHz, 
CDCl3) δ 8.79-8.69 (m, 2H), 8.15-8.07 (m, 2H), 7.78-7.69 (m, 2H), 7.62-7.56 (m, 1H), 
7.54-7.27 (m, 11H), 7.16 (dd, J = 9.3, 2.0 Hz, 1H), 7.10 (d, J = 8.9 Hz, 1H), 6.33-6.24 (m, 
2H), 5.79-5.58 (m, 3H), 4.97 (dd, J = 9.5, 2.0 Hz, 1H), 4.68 (d, J = 2.4 Hz, 1H), 4.34 (d, J 
= 8.5 Hz, 1H), 4.20 (d, J = 8.5 Hz, 1H), 3.97 (d, J = 6.8 Hz, 1H), 3.60-3.43 (m, 2H), 2.69-
2.52 (m, 4H), 2.53-2.29 (m, 3H), 2.23-2.12 (m, 4H), 2.02-1.85 (m, 6H), 1.85-1.75 (m, 4H), 
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1.22 (s, 3H), 1.16 (s, 3H), 0.80 (s, 9H), –0.03 (s, 3H), –0.30 (s, 3H); 13C NMR (126 MHz, 
CDCl3) δ 202.2, 172.3, 171.6, 170.1, 169.3, 167.5, 167.0, 161.5, 160.1, 148.9 (d, J = 
243.2 Hz, 3.78 Hz), 147.6, 141.0, 140.8 (d, J = 7.56 Hz), 139.4 (m), 139.2 (dd, J = 226.8, 
5.04 Hz), 138.2, 134.1, 133.9, 132.8, 132.1, 130.3, 129.1, 129.0, 128.91, 128.89, 128.2, 
127.2, 126.54, 126.49, 117.0, 110.6 (d, J = 10.08 Hz), 109.9 (m), 84.2, 81.1, 78.8, 76.6, 
75.4, 75.3, 74.6, 71.5, 71.4, 56.2, 55.9, 47.0, 43.5, 39.3, 35.7, 33.5, 31.4, 26.5, 25.7, 24.2, 
23.2, 21.5, 20.9, 18.3, 14.8, 11.1, –5.0, –5.7; HRMS (ESI+) m/z 1299.4524 (M+Na+, 
C67H74F2N2O19SiNa requires 1299.4521). 
 
(2aR,4S,4aS,6R,9S,11S,12S,12bS)-9-(((2R,3S)-3-Benzamido-2-hydroxy-3-
phenylpropanoyl)oxy)-12-(benzoyloxy)-4-((4-(6,8-difluoro-7-hydroxy-2-oxo-2H-
chromene-3-carboxamido)butanoyl)oxy)-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-
3,4,4a,5,6,9,10,11,12,12a-decahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-
b]oxete-6,12b(2aH)-diyl diacetate (PB-GABA-Taxol, 2-7). Following general procedure 
B, 2-14 (16 mg, 0.013 mmol) yielded compound 2-7 (13 mg, 86%) as a yellow solid. 1H 
NMR (500 MHz, CDCl3) δ 8.81 (t, J = 6.0 Hz, 1H), 8.73 (d, J = 1.5 Hz, 1H), 8.11–8.05 (m, 
2H), 7.80–7.73 (m, 2H), 7.63–7.56 (m, 1H), 7.53–7.28 (m, 11H), 7.16 (dd, J = 9.4, 2.0 Hz, 
1H), 6.19 (s, 1H), 6.18-6.13 (m, 1H), 5.79 (dd, J = 9.0, 2.9 Hz, 1H), 5.65 (d, J = 6.8 Hz, 
1H), 5.54 (dd, J = 10.4, 7.2 Hz, 1H), 4.92 (dd, J = 9.6, 2.0 Hz, 1H), 4.81 (d, J = 2.9 Hz, 
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1H), 4.30 (d, J = 8.5 Hz, 1H), 4.17 (d, J = 8.5 Hz, 1H), 3.89 (d, J = 6.7 Hz, 1H), 3.53–3.39 
(m, 2H), 2.64-2.50 (m, 1H), 2.46 (dt, J = 17.3, 7.2 Hz, 1H), 2.36 (s, 3H), 2.31–2.26 (m, 
3H), 2.17 (s, 3H), 2.00–1.84 (m, 2H), 1.81 (s, 3H), 1.79 (s, 3H), 1.36–1.23 (m, 2H), 1.19 
(s, 3H), 1.15 (s, 3H); HRMS (ESI-) m/z 1161.3683 (M-H+, C61H59F2N2O19  requires 
1161.3680). 
 
Figure 2.14 Analytical HPLC profile of PB-GABA-Taxol (2-7) after preparative HPLC. 
Retention time = 18.0 min monitored by UV absorbance at 254 nm. Purity >97% by HPLC. 
 
5-((3-(((2aR,4S,4aS,6R,9S,11S,12S,12bS)-6,12b-Diacetoxy-9-(((2R,3S)-3-
benzamido-2-((tert-butyldimethylsilyl)oxy)-3-phenylpropanoyl)oxy)-12-
(benzoyloxy)-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-
2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-
methanocyclodeca[3,4]benzo[1,2-b]oxet-4-yl)oxy)-3-oxopropyl)carbamoyl)-2-(2,7-
difluoro-6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid (2-15). To a solution of 
piperidine (20%) in DMF (2 mL) was added 2-8 (10 mg, 0.010 mmol). The mixture was 
stirred at 22 °C for 10 min followed by complete removal of piperidine under reduced 
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pressure. To this crude intermediate in DMF (2 mL) was added Oregon Green 488 
Carboxylic Acid, Succinimidyl Ester, 5-isomer (Thermofisher Scientific, 5 mg, 0.011 mmol) 
and DIEA (5 µL). After stirring for 16 h, the reaction was concentrated under reduced 
pressure. The crude product was dissolved in DMSO (2 mL) and purified by preparative 
reverse phase HPLC (gradient: 90/10 H2O/MeCN to 100% MeCN over 20 min with 0.1% 
TFA added; retention time = 18 min (488 nm)) to afford 2-15 as an orange solid (6 mg, 
43%). HRMS (ESI+) m/z 1431.4731 (M+Na+, C77H78F2N2O21SiNa requires 1455.4732). 
 
5-((3-(((2aR,4S,4aS,6R,9S,11S,12S,12bS)-6,12b-Diacetoxy-9-(((2R,3S)-3-
benzamido-2-hydroxy-3-phenylpropanoyl)oxy)-12-(benzoyloxy)-11-hydroxy-
4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-
7,11-methanocyclodeca[3,4]benzo[1,2-b]oxet-4-yl)oxy)-3-oxopropyl)carbamoyl)-2-
(2,7-difluoro-6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid (Flutax-2 (b-Ala), 2-3). 
This compound is commercially available from Thermo Fisher Scientific (cat# P22310), 
but was synthesized for these studies as follows: using general procedure B, 11 (4 mg, 
0.0028 mmol) yielded Flutax-2 (b-Ala) (3 mg, 82%) as an orange solid. HRMS (ESI+) m/z 
1319.4038 (M+H+, C71H65F2N2O21 requires 1319.4048).  
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Figure 2.15 Analytical HPLC profile of synthetic Flutax-2 (b-Ala) after preparative HPLC. 
Retention time = 17.6 min monitored by UV absorbance at 254 nm. Purity >99% by HPLC. 
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Chapter 3 - Photochemical depolarization of mitochondria of living cells mediated 
by a fluorinated pyronin fluorophore 
 
3.1 Introduction 
As described in Chapter 1, mitochondria play crucial roles in metabolism, 
production of ATP, and specific signal transduction pathways.1 These functions rely on 
the integrity of the negative membrane potential across the mitochondrial inner 
membrane (Δψm = -120 to -180 mV, shown in Figure 3.1).2 If this membrane is 
depolarized, the production of ATP ceases, leading to cell death. Consequently, many 
diseases are associated with abnormal mitochondria, including cancer, obesity, 
cardiomyopathies and neurodegeneration.3-5  Hyperpolarized mitochondria are often 
observed in cancer, providing a potential target for therapeutics (shown in Figure 3.1).  
Due to the negatively charged environment within mitochondria, lipophilic cations 
are prone to permeate across the mitochondrial membrane and accumulate in the 
mitochondrial matrix. Because of this driving force, many lipophilic cationic fluorescent 
probes including rhodamines, pyronins, and others, have been used to study these 
organelles.6, 7 Whereas rhodamine derivatives have been widely investigated in vitro,6, 8, 
9 in vivo,10, 11 and as fluorescent chemosensors,12, 13 studies of analogues of pyronin B 
are more limited. However, pyronins have been used for cell cycle analysis,14 
bioimaging,15 as sensors of pH,16 nerve agents,17 cellular peroxynitrite,18 heavy metals,19 
ATP dynamics,20 proteases,21 and protein-protein interactions,22 
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Figure 3.1. The mitochondrial membrane potential is more negative than the potential 
across the plasma membrane of mammalian cells. Abnormal mitochondria have been 
associated with diseases in multiple different tissues. 
 
Small molecules that uncouple the electron chain of mitochondria, or that 
otherwise depolarize mitochondrial membranes, are important molecular probes with 
potential therapeutic applications.23 Compounds that use photochemistry to depolarize 
mitochondrial membranes are of substantial interest because they provide novel tools to 
study fundamental mitochondria biology.24, 25 However, existing photoactivatable probes 
rely on either UV-mediated cleavage of a nitrobenzyl group to release the uncoupler DNP 
from a mitochondria-targeting triphenylphosphonium salt25 or the production of reactive 
oxygen species by near-IR laser radiation of mitochondria-targeted silica-carbon 
nanoparticles.26 
In an effect to create more drug-like probes to study mitochondria, we synthesized 
a series of pyronin B derivatives (69-72 in Figure 3.2). Studies of the biological properties 
of these compounds were used to identify 2,7-difluoropyronin B (69) as a small molecule 
capable of depolarizing mitochondrial membranes upon irradiation with visible blue light. 
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Figure 3.2. Chemical structures of the known fluorophores rhodamine 123 (17) and 
pyronin B (68) compared with the novel compounds 2,7-difluoropyronin B (69), 9-
ethylamino difluoropyronin B (70), pyronin azetidine (71), and 2,7-difluoropyronin 
azetidine (72).  
 
3.2 Synthesis of pyronins 
 To design novel analogues of pyronin shown in Figure 3.2, we proposed to 
incorporate fluorine in compounds 69, 70, and 72 because this modification has been 
widely used to improve the chemical and biological properties of therapeutics and 
fluorescent probes.27 Among other effects, fluorination can profoundly affect drug 
metabolism and chemical reactivity. When incorporated into fluorophores such as 
Pennsylvania Green, fluorine has been shown to confer enhanced photostability and 
fluorescence in acidic environments compared to the non-fluorinated analogue Tokyo 
Green.28 A similar improvement of photostability is observed in the fluorinated coumarin 
Pacific Blue compared to its non-fluorinated parent compound.29 Additionally, substitution 
of alkyl chains with cyclic azetidine analogues has been used to improve brightness and 
other photophysical properties of fluorophores, and 71 and 72 were designed to explore 
this modification.30, 31 The synthesis of these analogues of pyronin B is shown in Scheme 
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3.1. This route is based on a previously published method for the preparation of 
difluoroxanthones.32 Briefly, the inexpensive benzophenone starting material 73 is 
converted to difluoroxanthone (74) by nucleophilic aromatic substitution with diethylamine 
followed by cyclization under basic conditions. The intermediate 74 was reduced with 
borane dimethylsulfide (BH3-SMe2) and oxidized with 2,3-dichloro-5,6-
dicyanobenzoquinone (DDQ), followed by precipitation with trifluoroacetic acid (TFA) to 
provide 2,7-difluoropyronin B (69) as the TFA salt. 2,7-Difluoropyronin azetidine (72) was 
prepared from using a similar method with azetidine. To make 9-ethylamino 
difluoropyronin B (70), the intermediate 74 was first triflated with trifluoromethanesulfonic 
anhydride (Tf2O), substituted by ethylamine, and the desired product precipitated with 
TFA. 
 
Scheme 3.1. Synthesis of 2,7-difluoropyronin B (69), 2,7-difluoropyronin azetidine (72), 
and 9-ethylamino difluoropyronin B (70). Reaction conditions: a) Et2NH, 90 °C. b) KOH, 
DMSO, Reflux. c) BH3-SMe2. d) DDQ. e) TFA. f) Azetidine, DIEA, MeCN, 100 °C. g) Tf2O. 
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 Synthesis of the pyronin azetidine (71) required an alternative route involving 
triflation of xanthone 77 with Tf2O to provide intermediate 78, followed by substitution with 
azetidine to give xanthone 79. This compound was reduced with BH3-SMe2, oxidized with 
DDQ, and precipitated with TFA to form the pyronin azetidine salt. 
 
Scheme 3.2. Synthesis of pyronin azetidine. Reaction conditions: a) Tf2O, pyridine, 90 °C, 
12 h. b) Azetidine, DIEA, MeCN, 150	°C, 12 h. c) BH3-SMe2 d) DDQ. e) TFA. 
 
3.3 Photophysical properties of pyronins 
 Pyronin B and its structurally similar N, N-dimethylamine analogue Pyronin Y are 
reported to be highly fluorescent. To compare new pyronin analogues with parent 
compounds, absorbance and emission spectra in ethanol were acquired. As shown in 
Figure 3.3 A, the maximal absorbance and emission of 71 and 72 are similar to the parent 
compound 68, with the maximum absorbance of ca. 553 nm, whereas the maximum 
emission is ca. 574 nm. The maximal absorbance and emission of difluoropyronin B (69) 
was somewhat red shifted. In contrast, the spectra of ethylaminopyronin (70) were largely 
blue-shifted, with maximal absorbance at 443 nm and emission at 531 nm. 
 The extinction coefficients of pyronins were determined at the maximum 
absorbance wavelength in ethanol as shown in Figure 3.3 B. In comparison to the non-
fluorinated pyronin B 68 (ε = 64360 M-1cm-1) and azetidine pyronin 71 (ε = 72740 M-1cm-
1), the fluorinated 69 and 72 exhibited slightly decreased extinction coefficients of 61610 
M-1cm-1 and 67740 M-1cm-1, respectively. Additionally, the azetidine analogues 71 (ε = 
72740 M-1cm-1) and 72 (ε = 67740 M-1cm-1) showed higher extinction coefficients than 68 
a
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(ε = 64360 M-1cm-1) and 69 (ε = 61610 M-1cm-1), as expected. The blue shifted fluorophore 
70 exhibited a lower extinction coefficient (ε = 43390 M-1cm-1) compared to the parent 
fluorophore 68. 
 
Figure 3.3. Normalized absorbance (Abs.) and emission (Em.) spectra of pyronins in 
ethanol (A) and determination of extinction coefficients at absorbance λmax (B). 
 
3.4 Accumulation of pyronins in cells 
 To examine the subcellular distribution of pyronin analogues, HeLa cervical cancer 
cells were treated with concentrations of 2 µM or 10 µM (1 h). Confocal images were 
obtained upon excitation with 405 nm, 488 nm, and 532 nm lasers. The fluorescence 
emission was collected using blue (425-550 nm), green (500-650 nm) and yellow (550-
650 nm) channels as shown in Figure 3.4. Based on their absorbance and emission 
spectra, pyronins, 68, 69, 71 and 72 were proposed to be excited at 488 nm or 532 nm 
 
 
92 
detected with the green and yellow channels. The blue shifted fluorophore 70 should be 
excited at 405 nm or 488 nm and detected with the blue and green channels. As expected, 
68, 69 and 71 were observed with the both green and yellow channels, whereas 70 
observed mainly with the blue channel. Surprisingly, despite the high in vitro fluorescence 
of compound 72, it didn’t exhibit cellular fluorescence. No significant uptake was observed 
in cells even after treatment with a concentration of 10 µM, suggesting that the enhanced 
electrophilicity in this particular pyronin due to the combination of fluorination and the 
strained azetidine ring might result in rapid reactivity toward cellular nucleophiles and 
abolishment of fluorescence.  
Similar to the positive control Rhodamine 123, a hydrophobic cation known to be 
localized in mitochondria, 68, 70 and 71 (2 µM) were observed to accumulate in tubular 
organelles. This same localization pattern was observed for 69 (10 µM), suggesting that 
these compounds specifically accumulate in mitochondria. Interestingly, 70 also 
appeared to label vesicles in the cytosol. 
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Figure 3.4. Confocal fluorescence and DIC micrographs of HeLa cells treated with 17, 
68-72. Cells were washed with media prior to imaging. Scale bar = 25 µm. 
 
To further confirm that pyronins 69 and 71 specifically localize in mitochondria, we 
treated HeLa cells with these compounds and Mitochondria Deep Red FM (32, MTDR, 
100 nM). This commercially available fluorophore is spectrally orthogonal to these 
pyronins and specifically labels mitochondria. After incubation, confocal images were 
obtained with excitation at 488 nm and 532 nm. These images revealed that 69 (10 µM, 
1 h) or 71 (10 µM, 1 h) acquired in the green channel overlaid  (shown in yellow) with 
MTDR (100 nM, 5 min) acquired in the red channel, indicating that 69 and 71 specifically 
accumulate in mitochondria (Figure 3.5, A and D). Compound 70 was also observed to 
localize in mitochondria under these conditions (shown in Figure 3.5 B). However, this 
compound also labels lysosomes in cells, as evidenced by yellow overlaid vesicles upon 
co-treatment with 70 (10 µM, 1 h) and spectrally orthogonal lysotracker red (1 µM, 30 min, 
Figure 3.5 C).  
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Figure 3.5. Colocalization assay of probes 69, 70, and 71 with organelle markers 
respectively by confocal microscopy. (A) Cells treated with 69 (10 µM, 1 h) and  
mitotracker deep red (MTDR, 100 nM, 5 min). (B) Cells treated with 70 (10 µM, 1 h) and 
MTDR (100 nM, 5 min). (C) Cells treated with 70 (10 µM, 1 h) and lysotracker red (1 µM, 
30 min). (D) Cells treated with 71 (10 µM, 1 h) and MTDR (100 nM, 5 min). Cells were 
imaged without washing. Scale bar = 25 µm. The emission of 69, 71 and 72 was detected 
at 500-650 nm after excitation at 488 nm. The emission of MTDR was detected at 650-
750 nm after excitation at 635 nm. The emission of Lysotracker Red was detected at 600-
650 nm after excitation at 532 nm. The emission of 70 was detected at 425-550 nm after 
excitation at 405 nm.  
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 The mitochondrial membrane potential is commonly elevated in cancer cells.33 
Hence, in principle, selectivity for cancer cells over normal cells might be obtained by 
treatment with probes that are dependent on this membrane potential. To explore this 
concept, we dosed two different cell lines, the cervical cancer cell line HeLa, and the 
normal kidney cell line CV-1, which has a lower mitochondrial membrane potential. As 
expected, uptake of the positive control rhodamine 123 (17, 2 µM, 1 h) was less in CV-1 
cells compared with HeLa cells (Figure 3.6 D and C), suggesting that the mitochondrial 
membrane potential of CV-1 is lower than HeLa. When both cells were treated with 69 
(10 µM, 1 h), low fluorescence was observed in CV-1 in comparison to HeLa, suggesting 
that 69 depends on the membrane potential to accumulate in mitochondria. Additionally, 
these results suggest that one could gain selectivity for targeting of cancer cells using 69. 
 
Figure 3.6. Confocal images of HeLa (A, C) and CV-1 (B, D) cells. Cells were treated 
with 69 (10 µM, 1 h) or rhodamine 123 (2 µM, 1 h). Emitted photons were collected at 
500-600 nm upon excitation at 488 nm. Scale bar = 25 µm 
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3.5  Photochemical depolarization of mitochondrial membranes mediated by 69 
In contrast to 68, the subcellular localization of 69 was substantially altered after 
imaging for an extended period of time. Initially, 69 accumulates only in mitochondria of 
living cells, similar to the parent compound 68. However, after irradiation for 60 seconds 
at 488 nm, the fluorescence was observed to diffuse from mitochondria into the cytoplasm 
and nucleus, where it further accumulated in nucleoli (shown in Figure 3.7 A, B, D and E). 
Because other pyronins are reported to bind with RNA in nucleoli of fixed cells that lack 
polarized mitochondria, these results suggested that the blue (488 nm) laser enables 69 
to depolarize mitochondria. To test this hypothesis, we treated cells with 69 (10 µM, 1 h) 
and CCCP (10 µM, 5 min, Figure 3.7 F), a uncoupler known to depolarize mitochondria 
membrane, for comparison with cells treated only with 69 (10 µM, 1 h). After irradiation 
with blue light (60 s, Figure 3.7 E), essentially identical phenotypes of diffusion of 
fluorescence from mitochondria to cytosol and nuclei were observed, suggesting that 69 
can trigger mitochondrial depolarization upon irradiation with visible blue light. For 
comparison, we also treated cells with the parent compound 68 (10 µM, 1 h) and 
irradiated with blue light (60s, Figure 3.7 B) or treated with CCCP (10 µM, 5 min, Figure 
3.7 C). A similar phenotype was observed upon treatment with CCCP but not irradiation, 
indicating that the fluorine substituents on 69 are critical for the observed light-mediated 
depolarization of mitochondria. 
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Figure 3.7. Effects of blue light or the mitochondrial decoupler CCCP on fluorescence of 
68 and 69 in HeLa cells. Cells were imaged by confocal microscopy without washing. 
Scale bar = 25 µm. 
 
Pyronin Y, a dye with a structure similar to 69, has been widely used as a 
fluorescent marker for RNA.14, 34, 35 To examine whether RNA is a target of 69 in cells, we 
removed RNA from cells by fixation with paraformaldehyde and digestion with RNase (10 
µg/mL or 30 µg/mL), followed by treatment with 69 (10 µM, 1 h). Living cells treated with 
69 (10 µM, 1 h) provided a control. As shown in Figure 3.8 (A and B), nuclear fluorescence 
was observed only in fixed cells (B) but not in living cells (A) due to the lack of a 
mitochondrial membrane potential in fixed cells, further indicating that accumulation of 69 
in mitochondria is a dependent on this membrane potential. Upon treatment with RNase, 
this nuclear fluorescence dramatically decreased in a dose-dependent manner, providing 
evidence that RNA is a target of 69 or its metabolites after release from mitochondria. 
 
Figure 3.8. Confocal images of living HeLa cells (A) or fixed HeLa cells (B) treated with 
69 (10 µM, 1 h). Images of fixed cells treated with RNase (10 µg/mL, C or 30 µg/mL, D) 
following 69 (10 µM, 1 h) by confocal microscopy. Scale bar = 25 µm. 
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3.6  Investigation of the mechanism of action of photochemical depolarization of 
mitochondria mediated by difluoropyronin B 
We hypothesized that the unique chemical reactivity of 69 might be responsible for 
its ability to uniquely cause depolarization of mitochondria upon irradiation with blue light. 
Fluorination of this pyronin ring was predicted to generate a more electrophilic pyronin 
compared to the non-fluorinated parent compound. To investigate its potential reactivity, 
we measured absorbance spectra in aqueous solution upon addition of nucleophilic 
amines such as reduced glutathione (GSH), lysine (Lys), and bovine serum albumin 
(BSA). As shown in Figure 3.9, the absorbance spectra of the non-fluorinated pyronin 68 
was unchanged upon addition of amines, whereas 69 was observed to react with GSH, 
Lys and BSA. These results indicate that the fluorination of 68 to generate 69 enables 
reactivity towards these compounds, and this suggests that this increased reactivity might 
be responsible for this unique phenotype of cellular mitochondrial depolarization. 
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Figure 3.9. Absorbance spectra of 68 (10 µM) or 69 (10 µM) with addition of GSH (0, 5, 
50, 500, 5000 µM), Lys (0, 5, 50, 500, 5000 µM) and BSA (0, 1.5, 15, 150 µM) respectively 
in water by UV-Vis. 
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To identify whether 69 forms products upon irradiation with blue light, we acquired 
emission spectra using a highly sensitive fluorimeter. We hypothesized that spermine, a 
polyamine found in mitochondria at a high concentrations of approximately 1 mM,36 might 
be a target of 69. Mixing 100 µM spermine with 10 µM 69 in phosphate buffer resulted in 
loss of fluorescence (Shown in Figure 3.10 A), indicated that 69 likely reacts with 
spermine to form a non-fluorescent adduct. Moreover, upon irradiation of this solution 
with a blue LED light for 10 min, a new peak appears with a maximum emission 
wavelength around 540 nm. This peak is approximately 50 nm blue shifted compared to 
69, which exhibits maximum emission wavelength at 588 nm in this buffer. This blue-
shifted emission is very similar to ethylamino pyronin 70, suggesting that the new 
fluorescent species might be an aminopyronin formed by photooxidation of the non-
fluorescent adduct. It has been previously reported that depletion of spermine by 
transduction of cells with adenovirus encoding spermine acetyltransferase 1 causes loss 
of the mitochondrial membrane potential,37 indicating that reaction of 69 with spermine in 
mitochondria might result in depolarization. 
The reactivity of other amines commonly found in cells with 69 and blue light 
irradiation was also examined. The photochemical generation of aminopyronin products 
was also observed with glycine, GSH, lysine, Nα-Ac-lysine, Nε-Ac-lysine and glutamine 
(Shown in Figure 3.10 B). When compared to other pyronins (68, 71 and 72), only 69 
formed aminopyronins upon irradiation of BSA as a model protein, further demonstrating 
its unique reactivity (Shown in Figure 3.10 C).  
The degree of labeling (DOL) towards BSA by 69 was additionally examined. 
Labelled BSA was isolated by size-exclusion chromatography after its reaction with 
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pyronins. Measurement of absorbance by UV-Vis spectroscopy was used to calculate the 
dye concentration, protein concentration, and the DOL. As shown in Figure 3.10 D, 
consistent with Figure 3.10 C, only 69 was shown to label BSA. However, given that BSA 
has 59 lysine residues, where 30–35 are known to exhibit reactivity towards electrophiles 
(Thermo Scientific BSA product literature), a measured DOL of approximately 0.2 
suggests that 69 exhibits limited reactivity with this protein under these conditions. 
Furthermore, to determine whether the unique reactivity of 69 could be observed 
in living cells, we generated emission spectra of cells treated with 69 (10 µM, 1 h) by 
spectral scanning on a confocal microscope. As shown in Figure 3.10 E, fluorescence of 
cells treated with 69 has a maximum emission wavelength close to 540 nm whereas the 
control with 68 emits maximally at 580 nm. Consistent with the in vitro reactivity assay, 
69 is converted into aminopyronins in cells. Essentially, all of the signal detected in cells 
treated with 69 is derived from product aminopyronins. Additionally, we analyzed the 
fluorescence of the supernatant after treatment of cells with 68 and 69. Similar to the 
lambda scan confocal microscopy, 69 was able to converted into aminopyronins by cells 
resuspended in phosphate buffer, suggesting that after aminopyronins are formed in cells, 
they can rapidly diffuse across cellular plasma membranes and can be readily detected, 
indicating that a major cellular amine target of 69 is likely to be abundant small molecule, 
possibly reduced glutathione (GSH).  
To examine the potential for formation of an aminopyronin derived from GSH, we 
used LCMS to identify the MS of products from 69 reacting with this small molecule amine 
in vitro (Figure 3.10 G). In the absence of cells, a product was detected with MS of 664, 
supporting the formation of an oxidized GSH adduct. Thiopyronins that might be 
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generated by reaction of 69 with GSH or other thiols are predicted to be substantially 
more red-shifted38 than aminopyronins, and the fluorescence emission spectra were 
consistent with exclusive modification of the amine. To further confirm this amine target, 
future studies will attempt to identify this product by LC-MS after generation in cells 
resuspended in buffer. 
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Figure 3.10. Reactivity of 69 towards amines with and without irradiation by a blue LED 
(10 min). Fluorescence emission spectra (Ex. 488 nm) after treatment of 69 with amines 
in vitro: (A, B) spermine, glutathione, glutamine, glycine, lysine, Nα-Ac-lysine and Nε-Ac-
lysine in phosphate buffer (10 mM, pH = 7.4); (C) BSA protein in H2O. (D) Absorbance 
spectra of BSA after treatment with 68–72. (E) Fluorescence emission spectra (Ex. 488 
nm) of HeLa cells treated with 68 and 69 by lambda scan confocal microscopy. (F) 
Analysis of supernatant from cells treated with 68 and 69 by fluorimetry. (E) LCMS 
analysis of products resulting from reaction of 69 with glutathione after additional 
irradiation with blue light. 
 
3.7  Irradiation of 69 in cells with blue light generates reactive oxygen species 
Depolarization of mitochondrial membranes is always associated with increased 
reactive oxygen species (ROS) in cells. To examine whether irradiation of 69 with blue 
light generates ROS that might be involved in oxidization of amine adducts to fluorescent 
aminopyronins, we performed a dihydroethidium (DHE) assay that detects production of 
ROS in live cells by a change in fluorescence. Upon reaction with ROS, the weak 
fluorophore DHE becomes oxidized to ethidium and 2-hydroxyethidium, which further 
bind to nucleic acids to emit strong fluorescence. Changes in the fluorescence of the cell 
nucleus can be quantified by confocal microscopy. Quantification of intensity is done by 
drawing a region of interest around the nucleus and averaging data from more than 10 
cells for each treatment. As shown in Figure 3.11, no fluorescence was detected for 
negative controls, including cells treated only with DHE (5 µM), 68 (2 µM) and 69 (2 µM) 
separately. Antimycin A, an inhibitor of electron transport in mitochondria that induces 
generation of ROS was used as a positive control. A significant increase of fluorescence 
was observed when cells treated with DHE (5 µM) and antimycin A (20 µM), providing 
validation for this assay. When cells were treated with DHE and each pyronin, followed 
by irradiation for 1 min or 2 min, enhancement of fluorescence was observed for 69, 
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whereas no change in fluorescence for the parent compound 68, indicating 69 selectively 
induces formation of ROS over time under blue light irradiation.  
 
Figure 3.11. Effects of 68 and 69 on reactive oxygen species (ROS) in HeLa cells. Cells 
were treated with pyronins (2 µM) or the positive control compound antimycin A (20 µM) 
for 1 h followed by the ROS sensor dihydroethidium (DHE, 5 µM) for an additional 1 h. 
Fluorescence of individual cell nuclei was measured by image analysis of confocal 
micrographs (N ≥ 10).  
 
3.8  Cytotoxicity of pyronin analogues 
We further measured the cytotoxicity of pyronins towards HeLa cells and Jurkat 
lymphocytes by flow cytometry after treatment for 48 h. As shown in Figure 3.12, HeLa 
cells were more resistant to toxic effects of these compounds. Additionally, the parent 
compound 68 (IC50, Hela = 2 µM, IC50, Jurkat = 0.07 µM) was substantially more toxic than 69 
(IC50, Hela = 9 µM, IC50, Jurkat = 0.96 µM) towards both cell lines. This reduced cytotoxicity 
might be due to increased hydrolysis of 69 to the weakly toxic difluoroxanthone product 
(IC50, Hela = 51 µM, IC50, Jurkat = 17 µM). Additionally, 72 (IC50, Hela = 15 µM, IC50, Jurkat = 0.87 
µM) was less toxic than non-fluorinated 71 (IC50, Hela = 2 µM, IC50, Jurkat = 0.07 µM), further 
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supporting decreased cytotoxicity associated with fluorination. This is consistent with the 
cellular uptake assay, where no fluorescence was observed upon treatment 72, which 
could be a consequence of high reactivity of 72 towards biomolecules. 
 
 
Figure 3.12. Cytotoxicity of pyronins (68, 69, 70, 71 and 72) and difluoroxanthone (74) 
towards HeLa cells (A) and Jurkat lymphocytes (B) after 48 h treatment. 
 
3.9  Efflux of pyronin analogues 
 To assess whether pyronins might form stable fluorescent adducts with 
biomolecules in cells, we measured the half-life of each pyronin along with the positive 
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control Rhodamine 123 in Jurkat lymphocytes, a suspension cell line that is easy to 
analyze by flow cytometry. Cells were treated with each probe for 1 h followed by washing 
with fresh media to allow efflux of small molecules. Cellular fluorescence was immediately 
measured by flow cytometry. Analysis of fluorescence after different time points was used 
to generate kinetics data and half-lives were calculated using prism. As shown in Figure 
3.13, the positive control Rhodamine 123 strongly retained in mitochondria and exhibited 
a very long half-life of over 17 h. In contrast, the fluorescence of the pyronins was 
substantially lost over 1 h, especially 68 (t1/2 = 6 min) and 69 (t1/2 = 12 min), suggesting 
the rapid efflux of pyronins and their metabolites from cells. The longer half-life of 9-
ethylamino pyronindifluoropyronin B (70, t1/2 = 60 min) might be due to its retention in 
lysosomes as observed by confocal microscopy. 
 
Figure 3.13. Efflux of pyronins and Rhodamine 123 from Jurkat lymphocytes as 
quantified by flow cytometry. Cells were treated with probes (10 µM) for 1 h (37 °C). At 
each time point shown, cells were washed with fresh complete media prior to analysis of 
cellular fluorescence (Ex. 405 nm or 488 nm) by flow cytometry. Standard errors are 
estimated as ± 5 min. 
 
3.10  Conclusion 
 We synthesized four analogues of pyronin B (68) including 2,7-difluropyronin B 
(68), 9-ethylamino difluoropyronin (70), pyronin azetidine (71) and 2,7-difluoropyronin 
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azetidine (72) by either fluorination on pyronin ring or replacement of alkyl side chains 
with azetidine. One particular compound, 2,7-difluoropyronin B, exhibited unique 
biological activity resulting from its increased reactivity towards nucleophilic amines. In 
living cells, this compound accumulates in mitochondria but likely reacts with amines, 
such as spermine, GSH and proteins, to form adducts that can be further oxidized to 
fluorescent aminopyronins or hydrolyzed to generate a difluoroxanthone as shown in 
Figure 3.14. This formation of aminopyronins is enhanced by visible blue light. Irradiation 
by blue light also increases production of cellular ROS, and rapid depolarization of the 
mitochondrial membrane potential is observed. Aminopyronins diffuse from mitochondria 
into cytosol and bind to RNA in nuclei. The unique reactivity of 69 offers a novel tool for 
photochemical control of depolarization of mitochondria. 
 
Figure 3.1 Proposed mechanism of photochemical depolarization of mitochondria by 
2,7-Difluoropyronin B (69) with visible blue light. 
 
3.11  Future Plans 
Photochemical depolarization of mitochondria has been proposed as a strategy to 
improve cancer chemotherapy using nanoparticles that target these organelles.26 In this 
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approach, the activity of the ATP-dependent efflux pump P-gp is decreased upon 
depolarization of mitochondria. P-gp is a major mechanism of drug resistance, and 
methods for the inhibition of P-gp overexpressed cancer cells could lead to increased 
exposure of these cells to anticancer agents such as Taxol. To investigate whether DiF-
PyrB might exhibit similar effects on P-gp, it would be interesting to evaluate whether 
irradiation of cells treated with DiF-PyrB might enhance uptake of taxoids such as PB-
Gly-Taxol, a fluorescent mimic of taxol described in chapter 2. Preliminary data suggests 
that this approach might be successful, but additional studies are necessary to confirm 
these results. 
 
 
3.12  Experimental Section 
Determination of molar extinction coefficients and quantum yields 
Molar extinction coefficients (ε) were calculated using Beer’s Law: 𝐴 = 𝜀𝑏𝑐  (A is 
absorbance, b is path length and c is the concentration). Absorbance spectra were 
obtained from solutions of dry powders, and maximal absorbance versus concentration 
was analyzed by linear regression (including a zero intercept) with GraphPad Prism 7 
software (slope = ε). 
 
Relative quantum yields (ΦF) were calculated as: 𝑄; = 𝑄S ×
UV
UW
× XW
XV
× 3W
Y
3V
Y  where Q is the 
quantum yield, A is the absorbance, E is the area under curve (AUC) of the emission 
spectra, and n is the refractive index of the solution. Subscripts X and R refer to the 
sample and reference compound, respectively. The absorbance was extrapolated to yield 
values at low concentrations. Emission spectra were obtained with a fluorescence 
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spectrometer, and emission AUC values were calculated with GraphPad Prism 7. 
Extrapolated absorbance was plotted versus AUC and fitted by linear regression to 
provide the slope as X;
U;
 of the tested compound. The reference compound provided UV
XV
. 
 
Cell culture: Cell culture: HeLa cells (CCL-2) and CV-1 (CCL-70) were purchased from 
ATCC, and cultured in Dulbecco’s Modified Eagle Medium (DMEM, Sigma D6429). Jurkat 
lymphocytes (TIB152) were obtained from ATCC and cultured in RPMI-1640 medium 
(Sigma R8758). Media was supplemented with fetal bovine serum (FBS, 10%, Fisher 
Scientific, NC0924828), penicillin (100 units/mL), and streptomycin (100 µg/mL, Sigma 
P4333). Cells were maintained in a humidified 5% CO2 incubator at 37 °C.  
 
Confocal microscopy: Cells were added to an 8-well cover glass slide (Ibidi µ-Slide, 300 
µL, 20,000 cells/well) and allowed to proliferate for 24 h prior to addition of compounds. 
Compounds in DMSO stock solutions were serially diluted 1,000-fold in complete medium 
(final concentration of 0.1% DMSO) prior to addition to cells. Cells were treated with 
compounds at 37 °C for indicated length of time before imaging with a Leica SPE2 
confocal laser-scanning microscope (63X oil-immersion objective).  
 
Flow cytometry. Cells were analyzed with a Beckman Coulter Cytoflex S (B2-R0-V2-Y2) 
flow cytometer. Fluorophores were excited with 405 nm, 488 nm, and or 638 nm diode 
lasers and emitted photons were collected through 450/45 nm BP (Pacific Blue), 525/40 
nm BP (sensors), or 690/50 nm BP (PI) filters (FSC threshold = 500,000, flow speed = 
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fast, mixing time = 5 s, backflush time = 5 s, and cells were collected until 10,000 cells 
were counted).  
 
Analysis of efflux of small molecules from Jurkat cells by flow cytometry: Jurkat 
lymphocytes (300,000 cells/mL) in complete media were aliquoted into Eppendorf tubes 
(600 µL per tube before treatment). Fluorescent probes in DMSO stock solutions were 
added to each tube to achieve concentrations of 10 µM (0.1% DMSO) in triplicate. The 
resulting cells were incubated in Big Shot III Hybridization Oven at 37 °C for 1 h. Cells 
were centrifuged at 2000 rpm for 2 min to pellet. The supernatant was removed by 
aspiration, the cell pellets were washed once with fluorophore-free media (600 µL), and 
the cells were resuspended in media (600 µL). Cells in media (100 µL) were removed and 
analyzed by flow cytometry (t=0 min). The remaining cell suspension (500 µL) was 
incubated (37 °C) for an additional 30 min. Cells were centrifuged, washed, and analyzed 
by flow cytometry. Time points were recorded at 30, 60, 120, and 240 min. To keep the 
cell density constant, the media added for each round was 100 µL less than that of the 
previous cycle. Fluorescence was recorded on a cytoflex S flow cytometer and was 
normalized to the intensity observed at 0 min. Cellular fluorescence was analyzed with 
GraphPad Prism 7 using one phase exponential decay model. 
 
Analysis of ROS with DHE: HeLa cells were seeded on 8-well cover glass slides (Ibidi 
µ-Slide, 300 µL, 20,000 cells/well) and allowed to proliferate for 16 h prior to addition of 
compounds. Cells were treated with 69 or 68 (2 µM, 1 h, 37 °C), followed by addition of 
DHE (5 µM, 1 h). Cells were washed twice with complete media (300 µL) before imaging 
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by confocal microscopy. Cells subjected to irradiation were scanned with a 488 nm laser 
at 25% power. To quantify differences in nuclear fluorescence, regions of interest (ROI) 
were drawn around this organelle. Mean fluorescence values were generated and 
analyzed with GraphPad Prism 7. Antimycin A (20 µm) was used as a positive ROS-
generating control. Cells treated only with the pyronin were used to confirm that the signal 
from the nucleus originated only from DHE and its metabolites. 
 
Analysis of cytotoxicity: Cells were seeded on a 96-well plate in complete medium at 
8,000 cells / 200 µL per well 16 h prior to treatment. All compounds were serial diluted in 
DMSO and added to complete medium to achieve a 1:1000 dilution factor (0.1% DMSO 
in each well). The original media was removed from all wells by aspiration and replaced 
with the treatment media (200 µL) at the concentrations indicated. Plates were incubated 
for 48 h at 37 °C and cells were analyzed in triplicate. Following this incubation period, 
for HeLa cells, the media was aspirated and wells were washed with PBS (phosphate-
buffered saline, pH 7.4). Cells were then detached with a solution of trypsin and EDTA 
(50 µL) at 37 °C for 5 min followed by treatment with complete medium (100 µL). The total 
cell-count for each well was determined by flow cytometry, using a Beckman Coulter 
Cytoflex S flow cytometer, and populations of live cells were identified by light scattering. 
For Jurkat lymphocytes, cells were directly counted with the Cytoflex. Counts of viable 
cells for each treatment in triplicate were used to generate dose-response curves. These 
curves were fitted by non-linear regression with an inhibitor vs. response variable slope 
4-parameter model (GraphPad Prism 7) to determine IC50 values (Figure S7). Based on 
curve fitting, standard errors for cytotoxic IC50 values were ≤ 10%. 
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General experimental section. Chemicals were purchased from Sigma Aldrich, Alfa 
Aesar. 1H and 13C NMR spectra were acquired on Avance AVIII (500 MHz) or Varian 
VNMRS (400 MHz) instruments. Chemical shifts (δ) are reported in ppm referenced to 
CDCl3 (7.22 ppm for 1H and 77.0 ppm for 13C) or DMSO-d6 (2.50 ppm for 1H, 39.5 ppm 
for 13C). 1H coupling constants (JHH, Hz) and 13C coupling constants (JCF, Hz) are reported 
as: chemical shift, multiplicity (br = broad, s = singlet, d = doublet, t = triplet, q = quartet, 
m = multiplet, dd = doublet of doublets, ddd = doublet of doublet of doublets, dq = doublet 
of quartets, dt = doublet of triplets, ddt = doublet of doublet of triplets), coupling constant, 
and integration. High Resolution Mass Spectra (HRMS) were obtained at the Mass 
Spectrometry Laboratory at the University of Kansas on a Micromass LCT Premier. Thin 
layer chromatography (TLC) was performed on EMD aluminum-backed (0.20 mm) silica 
plates (60 F-254) and visualized with a UV lamp. Flash chromatography used ICN silica 
gel (200-400 mesh). Preparative HPLC was performed with an Agilent 1290 Infinity II 
instrument equipped with a Hamilton PRP-1 reverse phase column (250 mm length, 21.2 
mm ID, 7 μm particle size) with detection of absorbance at 215 and 254 nm. All non-
aqueous reactions were carried out using flame- or oven-dried glassware under an 
atmosphere of dry argon or nitrogen. Absorbance spectra were obtained using a 
semimicro (1.4 mL) UV quartz cuvette (Sigma-Aldrich, Z27667-7) on an Agilent 8452A 
diode array spectrometer. Fluorescence spectra were acquired using a SUPRASIL ultra-
micro quartz cuvette (PerkinElmer, B0631079) on a Perkin-Elmer LS55 Fluorescence 
Spectrometer (10 nm slit width). Melting points were acquired using a Bibby scientific 
SMP10 melting point apparatus and are uncorrected. Infrared spectra (IR) were recorded 
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with a Shimadzu GladiATR 10 Single Reflection ATR accessory. All commercial reagents 
and solvents were used as received unless otherwise noted. Yields are reported based 
on isolated material. Pyronin B (68) was purchased from Combi-Blocks as the HCl salt. 
3,6-Bis(diethylamino)-2,7-difluoro-9H-xanthen-9-one (74),39  2,2’,4,4’,5,5’-
hexafluorobenzophenone (73),39 and 3,6-bis(trifluoromethanesulfonate)xanthone (78)40 
were synthesized as previously reported. 
 
Synthetic procedures and compound characterization data 
General procedure A  
The corresponding 3,6-diaminosubstituted benzophenone (9.00 mmol), KOH (10 M, 12.0 
mL, 120 mmol), and DMSO (12 mL) were refluxed at 120 °C for 12 h. The resulting 
mixture was cooled to room temperature and subsequently placed in an ice bath for 1 h. 
The contents were further diluted with ice cold water (100 mL), and the resulting solid was 
collected by vacuum filtration. The crude solid was purified via recrystallization with 
CH2Cl2/hexanes.    
 
General Procedure B 
Step 1 - The corresponding 3,6-diaminosubstituted xanthone (0.314 mmol), 3.33 
equivalents of borane dimethyl sulfide (1.04 mmol), and THF (5.00 mL) were added to a 
round bottom flask and refluxed at 70 °C until starting material was consumed by TLC. 
When the reaction was complete, the flask was allowed to cool to room temperature. 
Methanol (5 mL) was added to quench the reaction. The solvent was removed under 
reduced pressure and the contents of the flask were passed through a silica gel plug (25 
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g of silica) in which the silica gel had been pretreated with a mixture of 25 mL CH2Cl2, 
and 2 mL trimethylamine using CH2Cl2 containing trimethylamine (0.1%) as the eluent. 
The solvent was removed under reduced pressure and placed under high vacuum (0.1 
mmHg) to remove all residual volatiles. The resulting solid material (xanthene) is unstable 
and slowly decomposes into the pyronin product, a process which is considerably 
accelerated by the use of DDQ as described in step 2.   
 Step 2 -The solid material from the previous step was dissolved in CH2Cl2 (7 mL) and 
treated with DDQ (0.377 mmol). The resulting mixture was stirred at 26 °C and monitored 
by TLC. Upon completion, trifluoroacetic acid (1 mL) was added to the reaction mixture 
and the resulting mixture was stirred for an additional 5 min. Volatiles were removed under 
reduced pressure. CH2Cl2 (7 mL) was added and the crude pyronin was stirred at room 
temperature for 1 h. The slurry was filtered under vacuum and the solid residue was 
washed with CH2Cl2 (5 mL). The filtrate was concentrated under reduced pressure. The 
residue was crystallized/recrystallized using toluene. During this process, the compound 
was vacuum filtered while dissolved in hot toluene to remove any insoluble impurities. 
The toluene filtrate was reheated to dissolve all solid material, slowly cooled, and allowed 
to stand at room temperature for 24-48 h before the pure pyronin crystals were recovered 
by vacuum filtration.   
 
N-(6-(Diethylamino)-2,7-difluoro-3H-xanthen-3-ylidene)-N-ethylethanaminium 
2,2,2-trifluoroacetate (2,7-Difluoropyronin B trifluoroacetate, 69). Using general 
ON
F
N
F
2.7-Difluoropyronin B
(69)
CF3CO2
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procedure B with a reaction time of 1.5 h for step 1 and 1.5 h for step 2, xanthone 73 was 
converted into pyronin 69. Pure crystals of 3 (147 mg, 92%) were obtained. m.p. 53-35 °C; 
1H NMR (400 MHz, CDCl3) δ 8.61 (s, 1H), 7.54 (d, J = 14.3 Hz, 2H), 6.93 (d, J = 7.4 Hz, 
2H), 3.67 (q, J = 7.0 Hz, 8H), 1.36 (t, J = 7.1 Hz, 12H); 13C NMR (101 MHz, CDCl3) δ  
160.3 (d, J C, F = 38 Hz, ArC2-F, ArC7-F), 155.1, 151.9, 149.4, 147.9 (d, J C, F = 11 Hz, 
ArC6-N), 145.4, 117.59, 116.4 (d, J C, F = 26 Hz, ArC8), 114.7, 114.4 (d, J C, F = 10 Hz, 
ArC1), 99.9 (d, J C, F = 5.4 Hz, ArC4, ArC5), 48.4, 13.2; IR (thin film) 2985, 2870, 1728, 
1605, 1466, 1281, 1134, 1072 cm-1; HRMS (ESI) m/z 359.1915 (M+, C21H25F2N2O 
requires 359.1935).   
 
Bis(4-(azetidin-1-yl)-2,5-difluorophenyl)methanone (75). 2, 2’, 4, 4’, 5, 5’-
hexafluorobenzophenone (73, 2.50 g, 8.61 mmol), azetidine hydrochloride (2.34 g, 25.0 
mmol), N,N-diisopropylethylamine (5.23 mL, 30.0 mmol), and acetonitrile (15 mL), were 
combined in a sealed tube and heated at 100 °C for 12 h. The resulting solution was 
concentrated under reduced pressure and the residue dissolved in CH2Cl2 (50 mL) and 
extracted with aq. HCl (1 M, 3 x 50 mL). The organic fraction was dried (anhydrous 
Na2SO4) and the solvent was removed under reduced pressure. The residue was 
recrystallized using CH2Cl2/hexane to provide 2.78 g (85%) of colorless crystals of 
benzophenone 75. m.p. 155-157 °C;  1H NMR (400 MHz, CDCl3) δ 7.27 (dd, J = 13.0, 6.0 
Hz, 2H), 5.97 (dd, J = 11.7, 7.2 Hz, 2H), 4.22–4.10 (m, 8H), 2.53–2.26 (m, 4H); 13C NMR 
(101 MHz, CDCl3) δ 185.3 (C=O), 158.8 (d, J C, F = 249 Hz, ArC6-F), 147.5 (d, J = 238 Hz, 
F F
O
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ArC2-F), 143.8 (m, ArC4-F), 117.3 (dd, J C, F = 22, 4.5 Hz, ArC5-F), 115.8 (m, ArC1-F), 99.5 
(dd, J C, F = 29, 5.1 Hz, ArC3-F), 53.6 (NCH2), 17.6 (CH2); IR (thin film) 2949, 2876, 1618, 
1589, 1450, 1375, 1159, 895, 742 cm-1; HRMS (ESI) m/z 387.1070 (M+Na+, 
C19H16F4N2ONa requires 387.1096). 
 
3,6-Di(azetidin-1-yl)-2,7-difluoro-9H-xanthen-9-one (76). Using general procedure A, 
benzophenone 75 was converted into 76. After recrystallization, colorless crystals (2.68 
g, 87%) of xanthone 76 were collected. m.p. 261-263 °C; 1H NMR (400 MHz, CDCl3) δ 
7.69 (d, J = 12.6 Hz, 2H), 6.09 (d, J = 7.3 Hz, 2H), 4.23–4.00 (m, 8H), 2.51–2.27 (m, 4H); 
13C NMR (101 MHz, CDCl3) δ 174.2 (C=O), 154.0 (ArC-O), 149.1 (d, J C, F = 242 Hz, ArC2-
F, ArC7-F), 144.6 (d, J C, F = 14 Hz, ArC3-N, ArC6-N), 111.6 (d, J C, F = 6.3 Hz, ArC1, ArC8), 
111.21 (d, J C, F = 21 Hz, ArC8a, ArC10a), 98.9 (d,  J C, F = 4.8 Hz, ArC4, ArC5), 53.7, 17.6; 
IR (thin film) 2953, 2884, 1618, 1530, 1464, 1352, 1252, 775 cm-1; HRMS (ESI) m/z 
365.1084 (M+Na+, C19H16F2N2O2Na requires 365.1078). 
 
1-(6-(Azetidin-1-yl)-2,7-difluoro-3H-xanthen-3-ylidene)azetidin-1-ium 2,2,2-
trifluoroacetate (2,7-Difluoropyronin azetidine trifluoroacetate, 72). Using general 
procedure B with a reaction time of 84 h for step 1 and 4 h for step 2, xanthone 76 was 
converted into pyronin 72. Pure crystals (114 mg, 76%) of 72 were obtained. m.p. > 
F F
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300 °C; 1H NMR (400 MHz, CDCl3) δ 8.41 (s, 1H), 7.35 (d, J = 11.6 Hz, 2H), 6.39 (d, J = 
7.0 Hz, 2H), 4.75–4.11 (br, 8H), 2.76–2.40 (m, 4H); 13C NMR (101 MHz, CDCl3) δ 13C 
NMR (101 MHz, Chloroform-d) δ 160.5 (d, J C, F = 37 Hz, ArC2-F, ArC7-F), 154.8, 151.5, 
149.0, 147.7 (d, J C, F = 15 Hz, ArC6-N), 145.6, 114.8 (d, J C, F = 21 Hz, ArC8), 114.0 (d, J 
C, F = 9.3 Hz, ArC1), 96.8 (d, J C, F = 5.4 Hz, ArC4, ArC5), 17.1, 1.0; IR (thin film) 3047, 
2951, 2874, 1659, 1614, 1504, 1362, 1287, 1180, 621 cm-1; HRMS (ESI) m/z 327.1292 
(M+, C19H17F2N2O requires 327.1309). 
 
3,6-Di(azetidin-1-yl)-9H-xanthen-9-one (79).  Acetonitrile (10 mL), KOH (10 M, 0.95 mL, 
9.5 mmol), azetidine hydrochloride salt (0.936 g, 10.0 mmol), and 3,6- 
bis(trifluoromethanesulfonate)xanthone (78, 0.492 mg, 1.00 mmol)40 were combined in a 
sealed tube vessel and heated to 180 °C for 12 h. Once cooled to 70 °C, the resulting 
slurry was filtered while hot under vacuum and the solid residue was washed with of 
MeOH in CH2Cl2 (1:9, 50 mL). The combined filtrate was concentrated under reduced 
pressure and the resulting residue was purified via column chromatography (3% MeOH 
in CH2Cl2 as the eluent). After removal of solvent under reduced pressure, the solid 
residue was recrystallized from DMSO; the crystals were washed with of cold water (50 
mL) to remove trace amounts of DMSO. Colorless needle crystals of pure 79 (64 mg, 
21%) were collected; 1H NMR (400 MHz, CDCl3) δ 7.91 (d, J = 8.7 Hz, 2H), 6.22 (dd, J = 
8.7, 2.2 Hz, 2H), 6.01 (d, J = 2.2 Hz, 2H), 3.97–3.81 (m, 8H), 2.41-2.20 (m, 4H); 13C NMR 
(101 MHz, CDCl3) δ 175.8, 158.0, 155.3, 127.4, 111.8, 107.9, 95.4, 51.4, 16.3; IR (thin 
O
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film) 3047, 2963, 2855, 1597, 1435, 1343, 1258, 1088, 1018, 795 cm-1; HRMS (ESI) m/z 
307.1458 (M+H+, C19H19F2N2O2 requires 307.1447). 
 
1-(6-(Azetidin-1-yl)-3H-xanthen-3-ylidene)azetidin-1-ium 2,2,2-trifluoroacetate 
(Pyronin azetidine trifluoroacetate, 71). Using general procedure B, the xanthene 
intermediate was formed after a reaction time of 3 h for step 1. To avoid decomposition 
of the final pyronin, it is imperative the xanthene intermediate is recrystallized in 
CH2Cl2/hexanes prior to step 2. The purified xanthene was converted to pyronin 71 using 
a reaction time of 12 h for step 2. Further purification by reverse phase HPLC provided 
pure crystals of 71 (65 mg, 47%); 1H NMR (500 MHz, DMSO-d) δ 8.66 (s, 1H), 7.80 (d, J 
= 8.9 Hz, 2H), 6.75 (dd, J = 8.9, 2.0 Hz, 2H), 6.46 (d, J = 2.1 Hz, 2H), 4.27 (t, J = 7.6 Hz, 
8H); 13C NMR (126 MHz, DMSO-d) δ 156.9, 156.4, 146.1, 133.4, 113.7, 112.5, 99.8, 51.8, 
15.4; HRMS (ESI) m/z 291.1487 (M +, C19H19N2O requires 291.1497). 
 
N-(6-(diethylamino)-9-(ethylamino)-2,7-difluoro-3H-xanthen-3-ylidene)-N-
ethylethanaminium 2,2,2-trifluoroacetate (9-Ethylamino difluoropyronin B, 70).  To 
a flame dried round bottom flask was added xanthone 7 (200 mg, 0.540 mmol). The flask 
was sealed and placed under argon. Acetonitrile (5.0 mL) was added and the resulting 
ON N
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suspension was treated dropwise with trifilate anhydride (110 µL, 0.650 mmol). The dark 
purple mixture was stirred for 20 min, during which all of the remaining solid solubilized. 
A solution of aqueous ethylamine (70% w/w, 1.00 mL, 12.6 mmol) was added dropwise.  
The mixture was stirred for 10 min and the resulting yellow/green solution was diluted 
with CH2Cl2 (20 mL) and extracted with H2O (3 x 20 mL). The resulting organic fraction 
was dried (anhydrous Na2SO4) and concentrated under reduced pressure. The remaining 
viscous yellow oil was passed through a plug of silica gel using CH2Cl2 to remove any 
nonpolar impurities followed by TFA:MeOH:CH2Cl2 (1:10:89) to elute the product. The 
solvent was removed under reduced pressure and the residue was crystallized using 
CH2Cl2/Hexanes to provide 237 mg of pure 4 (85%).  m.p. 117-118 °C; 1H NMR (400 MHz, 
DMSO-d) δ 9.54 (d, J = 5.9 Hz, 1H), 8.30 (d, J = 17 Hz, 1H), 7.94 (d, J = 17 Hz, 1H), 7.08-
6.58 (m, 1H), 4.21–3.89 (m, 2H), 3.70–3.36 (m, 8H), 1.42 (t, J = 7 Hz, 3H), 1.20 (d, J = 7 
Hz, 12H); 13C NMR (126 MHz, DMSO-d) δ 158.1 (d, J C, F = 35 Hz, ArC7-F), 153.91, 
153.23, 151.28, 149.3 (d, J C, F = 178 Hz, ArC2-F), 147.3 (d, J C, F = 176 Hz, ArC6-N), 143.8 
(d, J = C, F 29 Hz, ArC3-N), 114.8 (d, J C, F = 28 Hz, ArC8), 111.2 (d, J C, F = 28 Hz, ArC1), 
102.5, 100.0, 46.3, 42.8, 14.2, 12.9; IR (thin film) 3303, 2984, 2941, 1616, 1500, 1198, 
799 cm-1; HRMS (ESI) m/z 402.2345 (M+, C23H30F2N3O requires 402.2357). 
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Appendix A 
NMR Spectra 
 
Figure S1. 1H NMR (500 MHz, CDCl3) spectrum of PB-Gly-Taxol (56). 
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Figure S2. 1H NMR (500 MHz, CDCl3) spectrum of PB-b-Ala-Taxol (57).  
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Figure S3. 1H NMR (500 MHz, CDCl3) spectrum of PB-GABA-Taxol (58).  
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Figure S4. 1H NMR (500 MHz, CDCl3) spectrum of 59. 
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Figure S5. 13C NMR (126 MHz, CDCl3) spectrum of 59. 
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Figure S6. 1H NMR (500 MHz, CDCl3) spectrum of 60. 
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Figure S7. 13C NMR (126 MHz, CDCl3) spectrum of 60. 
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Figure S8. 1H NMR (500 MHz, CDCl3) spectrum of 61. 
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Figure S9. 13C NMR (126 MHz, CDCl3) spectrum of 61. 
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Figure S10. 1H NMR (500 MHz, CDCl3) spectrum of 62.  
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Figure S11. 13C NMR (126 MHz, CDCl3) spectrum of 62. 
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Figure S12. 1H NMR (500 MHz, CDCl3) spectrum of 63.  
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Figure S13. 13C NMR (126 MHz, CDCl3) spectrum of 63. 
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Figure S14. 1H NMR (500 MHz, CDCl3) spectrum of 64.  
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Figure S15. 13C NMR (126 MHz, CDCl3) spectrum of 64. 
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Figure S16. 1H NMR (500 MHz, CDCl3) spectrum of 65.  
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Figure S17. 13C NMR (126 MHz, CDCl3) spectrum of 65. 
  
 
 
145 
 
 
 
Figure S18. 1H NMR (400 MHz, CDCl3) spectra of 69. 
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Figure S19. 13C NMR (101 MHz, CDCl3) spectra of 69. 
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Figure S20. 1H NMR (500 MHz, DMSO-d6) spectra of 70. 
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Figure S21. 13C NMR (126 MHz, DMSO-d6) spectra of 70. 
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Figure S22. 1H NMR (500 MHz, DMSO-d6) spectra of 71. 
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Figure S23. 13C NMR (126 MHz, DMSO-d6) spectra of 71. 
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Figure S24. 1H NMR (400 MHz, CDCl3) spectra of 72.  
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Figure S25. 13C NMR (101 MHz, CDCl3) spectra of 72. 
  
 
 
153 
 
 
 
Figure S26. 1H NMR (400 MHz, CDCl3) spectra of 79.  
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Figure S27. 13C NMR (101 MHz, CDCl3) of 79. 
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Figure S28. 1H NMR (400 MHz, CDCl3) spectra of 75.  
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Figure S29. 13C NMR (101 MHz, CDCl3) spectra of 75.  
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Figure S30. 1H NMR (400 MHz, CDCl3) spectra of 76.  
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Figure S31. 13C NMR (101 MHz, CDCl3) spectra of 76.  
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Appendix B 
List of cell lines used  
Cell line Source Tissue Growth Media 
HeLa ATCC #CCL-2 Cervical Adherent DMEM 
PC-3 Dr. Matthew Levy Prostate Adherent DMEM/F12 
Jurkat ATCC # TIB-152 Lymphocyte Suspension RPMI 1640 
HCT-15 Dr. Liang Xu Colon Adherent RPMI 1640 
CV-1 ATCC #CCL-70 Kidney Adherent DMEM 
 
 
List of plasmids used 
 
Name Source Bacterial 
resistance 
Vector 
backbone 
Gene product 
pHaMDR-
EGFP 
Dr. Michael 
Gottesman 
Ampicillin pHa Human P-
glycoprotein-EGFP 
mCerulean-
ER-5 
Addgene 
#55366 
Kanamycin mCerulean Calreticulin-
Cerulean-KDEL 
DsRed2-ER-
5 
Addgene 
#55836 
Kanamycin DsRed2 Calreticulin-DsRed2-
KDEL 
mCerulean3-
Golgi-7 
Addgene 
#55420 
Kanamycin mCerulean3 β-1,4-
galactosyltransferase 
1-mCerulean3 
 
mEmerald-
Golgi-7 
Addgene 
#54108 
Kanamycin mEmerald β-1,4-
galactosyltransferase 
1-mEmerald 
 
mDsRed-
Golgi-7 
Addgene 
#55832 
Kanamycin mDsRed β-1,4-
galactosyltransferase 
1-mDsRed 
 
perbB1-
Citrine 
Addgene 
#40266 
Kanamycin pEYFP-N3 EGFR-Citrine 
pGFP-
Cytochrome 
C 
Addgene 
#41181 
Kanamycin pEGFP-C1 GFP-cytochrome C 
pAcGFP-C2-
hSphK2 
Addgene 
#84370 
kanamycin pAcGFP-C2 pAcGFP-
Sphingosine kinase2 
pDONR223-
SPHK1 
Addgene 
#23704 
Spectinomycin pDONR223 Sphingosine kinase1 
 
